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CHAPTER 1
GENERAL INTRODUCTION
BACKGROUND AND SIGNIFICANCE
Cardiac biology
The cardiovascular system is responsible for transporting the many constituents
of blood including electrolytes, nutrients, gases, and hormones, to and from all organs in
the body. Without the heart to create the appropriate amount of positive pressure,
organ perfusion would not occur, pH would become out of balance, and cellular
homeostasis would become severely disrupted. The general physiology and anatomy
of the heart are well defined (Fig. 1A,B). During the cardiac cycle, deoxygenated blood
enters the right atrium through either the superior or inferior vena cava and is then
pumped through the tricuspid valve into the right ventricle. It is then pushed through the
pulmonic valve into the pulmonary arteries and pulmonary circulation where it is
reoxygenated in the lungs.

The oxygenated blood re-enters the heart at the left atrium

by means of the pulmonary veins.

Ventricular diastole then ensues, during which

ventricular muscle relaxes. Pressure decreases in the left ventricle, and blood begins to
enter through the mitral valve which is forced shut after a critical volume is reached.
Contraction of the left atrium pushes a small amount of blood into the nearly full
ventricle, increasing its pressure just prior to ventricular systole. Immediately after, left
ventricular muscle cells contract and force the oxygenated blood through the aortic
valve into the aorta and subsequent arterial circulation [1].
The left ventricular wall of the heart is responsible for generating the immense
pressure necessary to circulate blood throughout the body. It is composed of three
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Figure 1. Cardiac anatomy and blood flow. (A) Blood returns to the heart through the
superior and inferior vena cava, enters the right atrium and is pumped into the right ventricle.
It then moves through the pulmonary arteries to the lungs, is reoxygenated, and flows into the
left atrium through the pulmonary vein. The left ventricle fills, with additional blood being
forced into the chamber through the mitral valve by the right atrium. Ventricular contraction
then pushes the blood into the aorta and throughout the body (arrows, blood flow). (B) The
myocardium lies between an inner epithelial layer (endocardium) and an outer connective
tissue layer (epicardium), and consists of stacks of muscle cells known as cardiomyocytes.
The myocardium is most dense in the left ventricle, as significant force is needed to drive
blood through the body. (C) Rows of cardiomyocytes arrange in parallel to form the
myocardium. Figures modified from various sources [2-4].

tissue layers: the endocardium, myocardium, and epicardium (Fig. 1B). The inner-most
layer, the endocardium, consists of epithelial cells that make contact with blood entering
the chamber. The myocardium (medial layer) is the location of the heart muscle cells
responsible for contraction during systole. The outer layer is a protective tissue known
as the epicardium. The myocardium represents the majority of the left ventricular wall,
and is composed of layers of cardiomyocytes (heart muscle cells) running in parallel
(Fig. 1C), connected cytoplasmically by channels known as gap junctions. Studying the
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myocardium at the cellular level is essential to understanding the underlying pathologies
involved in cardiomyopathies such as cardiac hypertrophy.
The major histological features of the cardiomyocyte include: 1) numerous rows
of myofibrils consisting of segments of interdigitating myosin and actin filaments called
sarcomeres (Fig. 2A); 2) a cytoplasmic membrane structure similar to endoplasmic
reticulum (ER) known as the sarcoplasmic reticulum (SR); 3) invaginations of the

Figure 2. Myofibrillar structure. The main constituent of the cardiomyocyte is the myofibril.
These long cylindrical structures themselves are made of many sarcomeres stacked in series,
containing multiple types of contractile filaments. (A) An electron micrograph of the interior of
a cardiomyocyte highlighting multiple myofibrils running in parallel. The sarcomere, the area
between two Z-lines in a myofibril, is the contractile unit in the cell. (B) Myofibrils are wrapped
in a network of endoplasmic reticulum-like compartments known as sarcoplasmic reticulum or
SR. In the free SR, located between Z-lines, the Ca2+-ATPase SERCA2a pumps Ca2+ into the
SR network. The Ca2+ is then released at junctional SR located on Z-lines, through the
ryanodine receptor after external Ca2+ entering through Ca2+ channels in the cell membrane
(SL)/T-tubules triggers activation. Modified from Gottlieb et al. and Sommer et al. [5-6].

sarcolemma (cell membrane) called T-tubules; and 4) a large number of mitochondria
running next to the myofibrils, to provide adequate ATP for cross-bridging termination
and to fuel sarco/endoplasmic reticulum Ca2+-ATPases (SERCA2a) [1, 7].

The
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sarcomere, the most basic myofibril contractile unit, is bordered on both ends by Z-lines
(Fig. 2A). Z-lines are the predominant sites of junctional SR, where SR membrane Ca2+
channels known as ryanodine receptors (RyR2) reside in close proximity to T-tubules
that provide access to extracellular Ca2+ (Fig. 2B) [6].
The junctional SR/T-tubule interface is critical for cardiomyocyte contraction, as it
is the site where calcium-induced calcium release (CICR) is initiated.

Adjacent

cardiomyocytes
alter
membrane
potentials
through

gap

junctions,
leading

to

sarcolemmal
depolarization,
which
L-type

causes
Ca

2+

channels in Ttubules
open.

to
The

Figure 3. Calcium-induced calcium release. Depolarization of the
heart cell membrane causes the L-type Ca2+ channel (CC) in the T-tubule
to open, allowing Ca2+ to bind RyR2s located in the junctional SR
membrane. The RyR2s then open, and Ca2+ moves into the cytoplasm,
triggering contraction. Afterwards, Ca2+ is either pumped out of the cell
by the Na+/Ca2+ exchanger (NCX) or back into the SR by SERCA2a
(SERCA), during which time CSQ2/Trd1/Jct complexes promote RyR2
refractory periods. Modified from Berridge et al. [8].

influxing extracellular Ca2+ binds the cytoplasmic side of junctional SR RyR2 channels
which then open, allowing large quantities of SR Ca2+ to move into the cytoplasm. the
Ca2+ subsequently binds troponin T, which releases tropomyosin bonds to actin and
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triggers contraction.

Ca2+ is then either pumped out of the cell by the Na+/Ca2+

exchanger (NCX) or back into the SR by SERCA2a, during which time cardiac
calsequestrin (CSQ2), triadin-1 (Trd1), and junctin (Jct) theoretically interact to cause a
RyR2 refractory period (Fig. 3) [8-9].
Calsequestrin
Calsequestrin (CSQ) is a major luminal protein of the junctional SR in muscle,
where it is thought to play a role in excitation-contraction coupling [10-16]. While both
skeletal CSQ (CSQ1) and cardiac CSQ (CSQ2) are expressed in skeletal muscle, only
CSQ2 is present in cardiac muscle, where it is the major Ca2+ binding protein [17]. In
fact, previous studies have hypothesized that nearly 50% of Ca2+ stored in
cardiomyocyte SR is bound to CSQ2 [18], which is reasonable given its ability to bind
large amounts of free Ca2+ (35-40 mol Ca2+/mol CSQ2) [19-20]. CSQ2 shares structural
properties with classic resident ER proteins such as GRP94 and calreticulin, although
CSQ2 lacks the C–terminal KDEL retrieval sequence along with any other known
targeting sequence [17, 21]. These properties allow CSQ2, through an unknown ER
retention mechanism, to evade secretion and become concentrated in junctional SR
[10-11, 16, 22]. Recent data supports the hypothesis that CSQ2 retention in ER results
from its polymerization [23].
Enrichment of CSQ2 in secretory pathway compartments may be related to its
tendency to polymerize in the presence of increasing Ca2+. A model for Ca2+-dependent
CSQ polymerization has been developed based upon crystal structure, showing linear
front-to-front and back-to-back CSQ chain formation [24-26]. As luminal SR Ca2+ levels
increase, CSQ begins front-to-front polymerization due to the lesser charge on its N-
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A further increase in Ca2+ causes back-to-back polymerization as more

terminus.

cations are needed to shield C-terminal acidic residues.

High luminal Ca2+ levels
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CSQ
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In addition
to
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CSQ2
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Figure 4. CSQ2 polymerization. As luminal SR Ca2+ levels increase,
CSQ2 begins front-to-front polymerization due to the lesser charge on its
N-terminus.
Further increases in Ca2+ cause back-to-back
polymerization as more cations are needed to shield C-terminal acidic
residues. High luminal Ca2+ levels lead to formation of CSQ2 linear
polymers with front-to-front and back-to-back binding. Modified from
Park et al. [26].

thought to interact
with cardiac RyR2, the SR integral membrane protein responsible for supplying the
cytosolic Ca2+ necessary for sarcomeric contraction. As proposed by Gyorke et al.,
CSQ2 serves as a Ca2+ sensor for the RyR2, promoting a channel refractory period in
times of low luminal Ca2+ [9]. CSQ2 binds in low Ca2+ to either Trd1 or Jct, both of
which may be tethered to the luminal side of the RyR2 in junctional SR. This is thought
to inhibit RyR2 activity. As luminal Ca2+ concentrations increase, CSQ2 binds more
Ca2+ and consequently becomes less tightly bound to Trd1 or Jct allowing stimulation of
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channel activity. Eventually Ca2+ levels are high enough to cause CSQ2 dissociation
from

the

complex,
allowing

the

RyR2 to reach
maximal activity
(Fig. 5).
CSQ2overexpressing
and

CSQ2-null

transgenic mice
have

been

developed in an

Figure 5. CSQ2 modulation of RyR2. CSQ2 is thought to serve as a
Ca2+ sensor for the RyR2, promoting a refractory period for the channel
in times of low luminal Ca2+. CSQ2 binds to either Trd1 or Jct in low
Ca2+, inhibiting the RyR2. Increases in luminal Ca2+ concentration cause
CSQ2 to become less tightly bound to Trd1/Jct allowing stimulation of
channel activity. Eventually Ca2+ levels are high enough that CSQ2
dissociates from the complex and the RyR2 becomes maximally active.
Modified from Gyorke et al. [9].

attempt to determine CSQ2 protein function in vivo [27-28]. Overexpressing animals,
with approximately 10-fold increases in cardiomyocyte CSQ2, suffer from severe
hypertrophy causing heart mass and cell size to increase 2-fold [27]. In knockout mice,
a hypertrophic phenotype was also reported, along with increased diastolic Ca2+ leak
with pathology similar to a disease in humans caused by CSQ2 mutation, known as
catecholaminergic polymorphic ventricular tachycardia (CPVT) [28-29]. Interestingly,
both overexpression and knockout transgenic models show a significant decrease in
Trd1 and Jct levels. Correspondingly, Trd1-null mice show a significant decrease in
CSQ2 and Jct levels, highlighting a potential interdependence between the three
proteins. A summary of the effects of CSQ2 knockout, along with Trd1-null data, can be
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seen in Table 1, modified from Knollmann [30]. Because changes in CSQ2 levels are
believed to be due to translational regulation [29], it would be beneficial to determine the
Table 1. Major features of CSQ2-null and Trd1-null mice.

site of CSQ2 synthesis.
Even without knowledge of the location of CSQ2 translation, it has still been
possible to obtain data regarding trafficking pathways based upon electrospray
ionization mass spectrometric analysis of the intact protein [31]. Information regarding
CSQ2 trafficking results from the ability of mass spectrometry to visualize the entire
repertoire of CSQ2 structures (glycoforms and phosphoforms) that exist in each
experimental system [31-32]. An N-linked glycan is added to CSQ2 co-translationally
(Man9GlcNAc2Glu3) in rough ER, and subsequently undergoes mannose trimming
upon exposure to various secretory compartments and their respective mannosidases
(Fig. 6) [31-32]. CSQ2 glycoforms differing in single mannose sugars (∆162 Da) are
easily discernable in CSQ2 mass spectra, allowing direct visualization of changes that
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Figure 6. N-Linked glycosylation. The standard N-linked glycosylation pathway begins with
co-translational transfer of the core oligosaccharide. Following successful folding of proteins in
the ER, the glycan Man9GlcNAc2 remains intact. An ER mannosidase I produces the Man8
form.
Subsequent mannose trimming is generally associated with ER and Golgi
compartments, but this process has not been examined in heart. CSQ2 glycan does not
contain N-terminal GlcNAc. Modified from Helenius et al. [32].

reflect trafficking pathways.

A second important modification of CSQ2 is the

phosphorylation of its multiple C-terminal serines (Fig. 7, in canine
can also be directly visualized (∆81 Da).

378, 382, 386

Ser) which

Between the possible combinations of

mannose and phosphorylation states in CSQ2, twelve structural forms can be resolved
from native heart tissue [31]; yet all will run in a nearly single band with SDS-PAGE
analysis at approximately 55 kDa [33].
Based upon the distribution of CSQ2 glycan structures (Man9-Man1) in a normal
mammalian heart, CSQ2 can be separated into two distinct pools [31, 34-35]. The most
proximal glycoforms (Man9-6) also contain the highest levels of serine phosphorylation
[31]; in fact all CSQ2 molecules in the heart that have 6 or more mannoses are also fully
phosphorylated. This suggests that CSQ2 phosphorylation also occurs at a location
early in the secretory system. A second pool is represented by Man1-5 isoforms. This
second pool indicates further trafficking of CSQ2, but still represents trafficking that
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Figure 7. Features of CSQ sequences (sequences from NCBI database). (Left panel)
Human cardiac (black) and skeletal muscle CSQ (red) sequences are 60% identical, and
exhibit conserved glycosylation sites (2nd box from end of the full-length sequence). The
cleaved signal sequences are very different, and that difference is conserved among
species (upper right panel). Residues highlighted yellow are only examples of near
identity, for orientation. The cardiac specific tail is seen in all species, and contains CK2sensitive serine residues (indicated by black dots under the residues, in addition to yellow
highlight in left panel, red lettering in lower right panel). Dotted lines for Rat and Dog Ctermini (lower right panel) designate the fact that cardiac tail is uncertain, since skeletal
muscle CSQ sequences have not been reported.

does not involve the Golgi, as Golgi trafficking would lead to addition of more (terminal)
GlcNAc residues [31-32].

The second CSQ2 pool exhibits a lower level of

phosphorylation, consistent with data using polymerization-site mutants that shows that
the state of CSQ2 phosphorylation decreases with anterograde movement through the
cell [23, 31, 34]. The distribution of glycoforms varies between cardiac and skeletal
muscle CSQs. In skeletal muscle CSQ, Man1 (a highly unusual glycoform) represents
as much as 80% of the total CSQ, while in cardiac muscle, CSQ2 Man1 levels are low
with Man3,4 (species dependent) dominating [31, 34-35]. In contrast to CSQ2 in heart,
CSQ2 overexpressed in nonmuscle cells consists of only Man9,8 glycoforms, indicative
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Figure 8.
CSQ2 Figure 8
masses are altered in
animal models of heart
failure (HF).
CSQ2
protein was purified
from Control and Heart
Failure animal heart,
then directly analyzed
by mass spectrometry.
CSQ2 molecules from
failed hearts were larger
than CSQ2 from control
hearts. Increased mass
is due to reduced
mannose trimming (∆
mass = 162 Da),
indicative of a higher
percentage of CSQ2 in
early ER (shaded). A
second change is a
decrease in more highly
processed
glycans.
Mass heterogeneity also
occurs due to C-terminal
CSQ2 phosphates (∆
mass = 81 Da). Mass
peaks
and
their
corresponding
glycan
structure
and
phosphorylation
state
are indicated across the
top
of
the
figure.
(Canine rapid-pacing
model) tissue from five
sham-treated and five
HF dogs was provided
by H. Valdivia, Univ.
Wisconsin.
Animals
underwent
ventricular
pacing, (HF = 220 beats/min) for 6-8 weeks to induce heart failure. (Canine micro-embolism
model) HF was caused by intracoronary microsphere injections leading to ischemic damage,
tissue from H. Sabbah, Henry Ford Health Systems, Detroit, MI. These data were obtained from
two Sham treated and two HF dogs, differences are more pronounced than in rapid-pacing.
(Mouse heart failure as a result of a canine CSQ2 transgene) transgenic mice with an MHCpromoter driving canine CSQ2 overexpression have been previously characterized. Adult mice
have severe heart failure and extreme cardiac hypertrophy. CSQ2 mass spectra were obtained
from two cohorts of animals: only 4 transgenic mouse ventricles were needed to obtain sufficient
CSQ2 for analysis, whereas 40 control mouse hearts were needed to obtain the Control mass
spectrum. The glycan structure (GlcNAc2Man8,9) on CSQ2 from these animals is almost
entirely indicative of ER mannosidase I, suggesting a completely altered trafficking.
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of its highly efficient ER retention.
In heart tissue from a canine model of heart failure, CSQ2 glycoforms and
phosphoforms are highly altered compared to control hearts (Fig. 8).

Mass

spectrometry of CSQ2 purified from these hearts shows a shift in the degree of
mannose trimming to a less trimmed pool of molecules. The underlying cause of this
apparent retrograde shift is unclear.

Additionally, an approximate doubling of the

Man8,9 pool occurred. This may suggest an increase in newly-synthesized CSQ2, still
in rough ER. Analysis of CSQ2 mass spectra further indicates a doubling of maximally
phosphorylated CSQ2, which could also reflect increased ER retention, or inhibition of
the CSQ2 transport system [35].
CSQ2 phosphorylation and protein kinase CK2
In 1991, Cala and Jones reported a cluster of three phosphorylation sites on
amino acids

378, 382, 386

Ser of canine CSQ2 [36]. These phosphorylation sites reside

within a cardiac specific tail region that is conserved in all cardiac isoforms in all species
(Fig. 7). Cardiac CSQ is phosphorylated on these sites in vivo [31, 36], with isolated
native CSQ2 showing approximately 50% phosphorylation. Skeletal muscle CSQ can
be phosphorylated in vitro on

353

Thr but is not phosphorylated in vivo [31, 36]. It was

subsequently determined that CSQ2 is the major substrate for endogenous
phosphorylation in heart homogenate (Fig. 9) [34]. Surprisingly, CSQ2 overexpressed
in nonmuscle cells is phosphorylated to a similarly high extent in vitro and in intact cells,
suggesting that the mechanism of CSQ2 phosphorylation may be conserved in all
mammalian cells [31]. While it has remained unclear what endogenous protein kinase
is responsible for phosphorylating CSQ2 on these sites in vivo, these authors showed
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Figure 9. In situ phosphorylation of CSQ2 by an unknown kinase. Expression of canine
CSQ2 in primary adult rat and canine heart cells was followed by metabolic labeling with 32Pi.
Canine (lanes 1–4) or rat (lanes 5–10) heart cell cultures were plated in a laminin-coated
sixwell dish. At 2 h post-plating, CSQ2 adenovirus (Ad.CSQ) was added (+), or cells were left
untreated (−). In one case, a non-phosphorylatable CSQ2 mutant virus (Ad.nonPP) was
added (lane 6). After 48 h of treatment, cells in two wells were harvested without labeling for
immunoblot analysis with anti-CSQ2 antibodies, and visualized with 125I-protein A and
autoradiography (lanes 1 and 2). Cells in other wells (lanes 3–8) were metabolically labeled
with 32Pi in label-free medium (DMEM) for 4 h, harvested in 0.1% Triton X-100 containing
buffer, centrifuged to remove insoluble material, and analyzed by SDS-PAGE and
autoradiography. Molecular weight standards (in kDa) are indicated. Heart cells from five
cultures were metabolically labeled for 4h (lane 3–7) whereas one sample was labeled for 8h
(lane 8). Two culture wells (lanes 9 and 10) were not radiolabeled but were extracted in 0.5 ml
1% Triton X-100-containing buffer and 50 µl added to a buffer containing 1 mM MgCl2 and 20
μM [γ -32P] ATP for 10 min at 37°C, before SDS-PAGE and autoradiography. Arrowheads
indicate CSQ2. Modified from Ram et al. [34].

that the sites were very sensitive in vitro to the protein kinase CK2 (formerly known as
casein kinase II).

Moreover, the phosphorylation sites are part of a consensus

sequence for CK2.
A

basic

structural

requirement

for

phosphorylation

by

CK2

is

the

“serine/threonine-X-X-aspartic acid/glutamic acid” motif [37-38]. The fourteen most Cterminal amino acids of canine CSQ2’s highly acidic tail, SDEESNDDSDDDDE,
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includes three serines that fit the consensus sequence [33, 36]. Although CSQ2 is an
SR luminal protein, and protein kinase CK2 is known to be a cytosolic or nuclear kinase
[39], an unknown mechanism must exist that allows for CSQ2 consensus site exposure
to CK2.
Over 500 protein kinases are represented by the human genome [40]. While
protein kinase CK2 is only one of many, it is one of the more active kinases in
numerous cell-types [41-42]. CK2 has been reported to phosphorylate hundreds of
distinct proteins, positively affecting cell proliferation/cell cycle progression and survival
by means of apoptotic inhibition and other various mechanisms [39, 41, 43-46]. Protein
kinase CK2 has become the focus of many oncological studies as levels have been
found to be elevated in human cancers and in transgenic overexpression models [41,
47-49].
Although CK2 is traditionally thought of as a holoenzyme, its biochemistry is
slightly more complex. CK2 is a tetrameric structure consisting of two catalytic and two
regulatory subunits [41, 44, 50]. The catalytic subunits, designated CK2α and CK2α′ in
humans [51], share approximately 90% homology [41], but may possess some level of
specialization as suppression of one subunit in mouse models does not produce a
complete compensation by the other [44, 52]. The regulatory subunits, known as CK2β,
participate in catalytic activity regulation and CK2 substrate selectivity, in addition to
maintaining tetramer stability during holoenzyme formation [41, 44, 50, 53].

CK2

regulatory subunits are identical in humans, performing equal roles [54], while they have
been reported to have separate identities in yeast where they are both essential [55].
To further complicate protein kinase CK2 research, an overall mechanism has not been
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deduced that summarizes the regulation of the kinase in cells; as some groups argue
that CK2 is constitutively active while others claim the influence of extracellular or
intracellular factors exists [41].
In addition to phosphorylating substrate as part of the holoenzyme, the individual
catalytic subunits CK2α and CK2α′ also have kinase activity independent of the tetramer
[56-57].

For example, both the holoenzyme and CK2α subunit were shown to

phosphorylate the cytosolic region of calnexin, a protein that shares many similarities
with CSQ2 [56]. Interestingly, both catalytic subunits have been shown to localize to the
cytosolic side of the ER and Golgi apparatus [57]. This data, collectively, suggests that
CK2 function and regulatory activity is quite complex and will require many future
studies to explain.
Highly specific inhibitors of CK2 have recently been developed and continue to
be improved due in part to the desirable anti-growth and anti-cancer activities they
exhibit [58-59].

The three main classes of CK2 inhibitors include:

1) condensed

polyphenolic compounds; 2) brominated benzimidazole/triazole derivatives; and 3)
derivatives of indolo quinazolines.

The second class is the most frequently and

successfully used [60]. The first of these ATP specific binding-site inhibitors of CK2,
5,6-dichloro-1-(β-ɒ-ribofuranosyl)-benzimidazole (DRB), was designed as a modified
version of adenosine.

Due to high experimental IC50 values and various off-target

effects, the popular DRB derivative 4,5,6,7-tetrabromobenzotriazole (TBB, Fig. 10) was
created by removing the sugar moiety and replacing its chlorines with bulkier bromines.
TBB was determined to be more potent and selective than DRB, and was also well
tolerated in live animals for multiple week spans [61]. A slightly modified version of
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Figure 10. Development of CK2 inhibitors. Inhibitors of protein kinase CK2 were initially
designed to mimic ATP structure. The specific inhibitor TBB was created to better fit the
unique ATP binding site of CK2. TBB was modified to produce DMAT, increasing the
molecules potency. TBCA represents the most potent and specific of this class of ATPcompetitive binding site inhibitors of CK2. Modified from Duncan et al. and Sarno et al. [61,
63].

TBB, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, Fig. 10) was found
to have an even higher potency, particularly when tested on cells in culture [62].
Currently, tetrabromocinnamic acid (TBCA, Fig. 10), the most specific CK2 inhibitor in
its class, has the lowest Ki (77 nM) [61]. It is thought that TBCA’s acrylic tail increases
van der Waals interactions, as it allows the brominated benzene ring to move [60].
Translation and translocation
Translocation of a newly translated protein into the ER lumen can occur after
translation is completed or concurrently with translation. The latter is referred to as cotranslational translocation.

During this process, signal sequences within a nascent

polypeptide are recognized by universally conserved factors in the cytosol and
membrane in order to mediate their selective targeting, translocation, and/or membrane
insertion (Fig. 11A) [64]. These events proceed when the hydrophobic core of the
signal sequence from the newly-synthesized protein protrudes from the ribosome and
becomes bound by the signal recognition particle (SRP), forming the SRP-bound
ribosome nascent chain complex (RNC). Interaction with the SRP receptor (SRP-R)
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allows the RNC to be targeted to the ER membrane, where it is then transferred to an
adjacent translocon followed by subsequent dissociation of the receptor-bound SRP
complex via GTP consumption. The ribosome binds to the Sec61 complex (Fig. 11B),
placing the signal sequence in close proximity to the translocating chain-associating
membrane protein (TRAM) and Sec61. If the signal sequence is recognized sufficiently
by the Sec61 complex, nascent chain insertion into the hydrophilic pore occurs with a
concurrent tightening of the bond between the ribosome and translocon. After further
elongation of the nascent chain, with its simultaneous translocation into the ER, it can
interact with the oligosacharyl transferase complex (OST) and signal peptidase complex
Figure 11.
Co-translational
translocation. (A) As translation
begins, the nascent chain signal
sequence protrudes from the
ribosome and is bound by SRP.
The complex is then trafficked to
an ER translocation site where
SRP is bound by the SRP
receptor and the ribosome binds
to the Sec61 pore complex. SRP
hydrolyzes GTP and releases
from the signal sequence,
ribosome, and eventually the
SRP receptor, leaving the signal
sequence to interact with Sec61
and TRAM complexes.
The
nascent chain is then further
synthesized
while
being
translocated into the ER lumen,
possibly receiving a glycan from
the OST complex and/or having
its signal sequence removed by
the SPC.
(B) A to scale
depiction of the rough ER
translocon showing theoretical
spacial approximations of various
complexes according to their
interactions with one another
(SP, signal peptidase). Modified
from Johnson et al. and Kalies et
al. [65-66].
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causing glycosylation and signal sequence cleaving, respectively, given the nascent
chain sequence permits [64, 66].
In part due to their extreme sequence diversity, it has been proposed that signal
sequence interaction with Sec61 is influenced by the signal’s intrinsic ability to attract
specific translocaton altering substrates, termed accessory factors [64].

These

modulators (accessory factors) can include membrane proteins, cytosolic proteins and
luminal proteins, i.e. chaperones. These substrates allow for proper positioning of the
nascent chain in preparation for subsequent translocation.
A universal property of signal sequences is their overall hydrophobic nature,
highlighted by the presence of an uninterrupted stretch of no less than six
nonhydrophilic residues [64]. When a comparison of signals is made between cardiac
and skeletal calsequestrin isoforms from various species, it can be noted that the
hydrophobic core is much more significant in skeletal muscle (Fig. 7). This difference in
hydrophobicity can affect interactions with the translocon apparatus [64], and may
contribute to the ability of cardiac calsequestrin to become phosphorylated during
translocation.
Significance
CSQ2 is capable of binding large amounts of Ca2+ within the secretory system in
cardiomyocytes. It is also thought to regulate RyR2 activity in junctional SR. Previously
published data shows that CSQ2 trafficking is altered in heart failure. A change in
CSQ2 localization within the cell could result in a significant Ca2+ microdomain shift,
capable of altering cellular biochemistry.

In order to investigate this pathological

phenomenon properly, the site of CSQ2 synthesis, and the protein’s subsequent
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trafficking pathway must first be elucidated. Additionally, possible effectors of CSQ2
trafficking, such as polymerization and phosphorylation, must be explored.
SPECIFIC AIMS OF DISSERTATION
Specific aim 1
Determine the pathway(s) of CSQ2 trafficking in the adult cardiomyocyte.
Hypothesis: CSQ-DsRed fusion protein exhibits retention in rough ER and reflects
normal CSQ2 trafficking pathways, involving polymerization.
Specific aim 2
Confirm the identity of CSQ2 kinase and determine the effects of CSQ2
phosphorylation. Hypothesis: CSQ2 is phosphorylated by protein kinase CK2, which
may affect its ER-retention.
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CHAPTER 2
EFFECTS OF A DYNAMIC MONOMER/POLYMER EQUILIBRIUM ON CARDIAC
CALSEQUESTRIN TRAFFICKING
ABSTRACT
CSQ2 is synthesized in rough ER but concentrates within the junctional SR
lumen where it becomes part of the Ca2+-release protein complex. To investigate CSQ2
trafficking through biosynthetic/secretory compartments of adult cardiomyocytes, CSQDsRed was overexpressed in cultured cells and examined using confocal fluorescence
microscopy.

By 48 h of adenovirus treatment, CSQ-DsRed fluorescence had

specifically accumulated in the nuclear envelope, where it co-localized with markers of
rough ER. From rough ER, CSQ-DsRed appeared to traffic directly to junctional SR
along a transverse (Z-line) pathway along which sec 23-positive (ER-exit) sites were
enriched. In contrast to DsRed direct fluorescence that presumably reflected DsRed
tetramer formation, both anti-DsRed and anti-CSQ2 immunofluorescence did not detect
the perinuclear CSQ-DsRed protein, but labeled only junctional SR puncta.

These

putative CSQ-DsRed monomers, but not the fluorescent tetramers, were observed to
traffic anterogradely over the course of a 48 h overexpression from rough ER towards
the cell periphery.

We propose a new model of CSQ2 and junctional SR protein

trafficking in the adult cardiomyocyte, wherein CSQ2 traffics from its juxtanuclear site of
biosynthesis, along contiguous ER/SR lumens in cardiomyocytes as a mobile monomer,
but is retained in junctional SR as a polymer.
INTRODUCTION
CSQ2 is a major protein of the junctional SR lumen in heart [11, 17, 67]. Its role
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in cardiomyocyte function is not yet clear, and may be multi-faceted [30, 68-69].
Overexpression studies in cultured myocytes support a role as a buffer of luminal Ca2+
[13], whereas data from CSQ2 knockout mice suggest a role in regulation of release of
Ca2+ through the RyR2 Ca2+ channel [28].

Interestingly, transgenic CSQ2

overexpressing [27] and knockout mouse models [28], also exhibit unexplained changes
in the levels of other junctional SR proteins, such as Trd1, Jct, and RyR2. These larger
changes in junctional SR protein levels highlight our poor understanding of the
biosynthetic/secretory system of the adult cardiomyocyte, of which ER, free SR, and
junctional SR are all a part [70].
Polymerization of CSQ is now thought to play a critical role in its biology, and is
predicted to occur in response to high luminal ER/SR Ca2+ [26, 68-69]. Although difficult
to study in myocytes, studies of CSQ2 overexpression in nonmuscle cells have clearly
shown how polymerization can also determine CSQ2 localization [23, 71-72].

In

mammalian nonmuscle cells, each CSQ isoform (cardiac or skeletal muscle) undergoes
polymerization that leads to its concentration in a specific cellular compartment.
Cardiac CSQ concentrates exclusively in the ER of all nonmuscle cells, whereas
skeletal muscle CSQ concentrates in the ER-Golgi intermediate compartment (ERGIC).
The distinct sites of localization for the two CSQ isoforms were the result of their
specific polymerization properties [71]. In this same way, polymerization of cardiac
CSQ in adult cardiomyocytes might occur specifically in junctional SR puncta, brought
about by the ionic milieu of junctional SR lumens.
Another biochemical property of cardiac CSQ that is likely to play a role in its
biology is phosphorylation on two or more serines in the cardiac-specific tail [31, 34, 36].

22

These C-terminal protein kinase CK2 consensus sequences are present in all cardiac
isoforms of CSQ and are exquisitely sensitive to CK2 in vitro. This modification is
believed to occur at the rough ER of the cardiomyocyte where it may affect CSQ2
translocation or CSQ2 trafficking from rough ER to junctional SR [34]. CSQ2 glycans
show trimming by cellular mannosidases with no other modification. Because N-acetyl
glucosamine (GlcNAc) would be found on CSQ2 glycans were CSQ2 to traffic to early
Golgi compartments [23, 73], it becomes likely that CSQ2 remains inside classical
mammalian ER.
In a canine tachycardia-induced model of hypertrophy that leads to heart failure,
CSQ2 glycosylation and phosphorylation are very significantly altered [35].

CSQ2

glycan structures in the hypertrophic heart show a two-fold increase in ER-localized
CSQ2 and a roughly two-fold increase in levels of phosphorylated CSQ2 in the ER [35].
The cellular processes underlying these changes have remained uncertain due to the
lack of understanding of CSQ2 biosynthesis and trafficking in the adult cardiomyocyte.
In the present study, we used confocal imaging techniques to investigate the
direct

fluorescence

of

CSQ-DsRed

along

with

a

complementary

indirect

immunofluorescence, to outline ER and SR regions in adult cardiomyocytes that parallel
putative CSQ2 compartmentation based upon on its biochemistry.
MATERIALS AND METHODS
Heart cell preparation and culture
This investigation conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH Publication No. 85-23,
revised 1996). Animal research was approved by the Wayne State University Animal
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Investigation Committee (protocol # A 06-07-07).

Excised Sprague-Dawley (Rattus

norvegicus) rat hearts were perfused using a Langendorff apparatus for 5 min before
enzymatic dissociation using a 40 ml solution consisting of Liberase Blendzyme (Roche)
types 1 and 2 (3 mg/6 mg) in Hank’s buffer containing 5 mM pyruvic acid, 1.2 mM
MgSO4, 5 mM creatine, 11 mM Glucose, 5 mM taurine, 5 mM carnitine and 0.1 mM
CaCl2 (20 min). Cells were titurated for 10 min at 37ºC, filtered, pelleted at 300 x gmax,
then washed in phosphate buffered saline (PBS) containing gradually increasing CaCl2
during 3 consecutive washes, to a concentration of 500 µM CaCl2, after which cells
were resuspended in Medium 199 containing 2% bovine serum albumin, 2 mM
carnitine, 5 mM creatine, 5 mM taurine, 2 mM L-glutamine, 2 mM Glutamax-1
(Invitrogen), ITS mixture (Sigma I3146), 100 units/ml penicillin G, 0.1 mg/ml
streptomycin and plated on laminin-coated dishes at 37ºC with 5% CO2.
CSQ plasmid and adenoviral constructs
CSQ constructs were generated from wild type canine cardiac CSQ cDNA λgt10
clone IC3A [33].

Adenoviral CSQ-DsRed (Ad.CSQ-DsRed) was created using the

AdEasy XL Adenoviral Vector System (Stratagene) after canine cardiac CSQ cDNA had
been cloned into pDsRed2-N1 vector as previously described [71]. Adenoviral CSQhemagglutinin (Ad.CSQ-HA) was previously described [23].
Adenoviral-mediated overexpression
Recombinant adenoviral treatment was carried out in cultured adult rat primary
cardiomyocytes as previously described [31].

Adenoviruses were added directly to

dishes 2 h post-plating at a multiplicity of infection (MOI) of 100. Virus treatments were
routinely carried out for 48 h before harvesting for biochemical analysis or fixing for
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microscopy as described below. Individual dishes and coverslips were incubated for
shorter or longer times as indicated.
Antibodies
Monoclonal antibodies specific to cardiac CSQ and RyR2 were the generous gift
of Dr. Larry Jones, Indiana University School of Medicine. Rabbit polyclonal antibodies
raised to canine CSQ2 were purchased from Abcam (ab3516). Rabbit polyclonal antiHA antibody was purchased from Sigma-Aldrich. Rabbit polyclonal anti-sec23 antibody
was obtained from Affinity BioReagents. Rabbit polyclonal anti-DsRed antibody was
purchased from Clontech.

Rabbit polyclonal antibodies specific to translocon-

associated protein complex (TRAP) and translocating chain-associated membrane
protein (TRAM) were the generous gift of Dr. Ramanujan Hegde, National Institute of
Child Health and Human Development, NIH. Alexa Fluor 488-conjugated goat antirabbit IgG, Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 568conjugated goat anti-mouse IgG secondary antibodies were purchased from Invitrogen.
Immunoblotting
SDS-PAGE was carried out according to Laemmli [74] on 7.5% acrylamide gels,
transferred to nitrocellulose membranes (0.45 µm, Bio-Rad Laboratories) and stained
with Amido black (Sigma). Immunoblotting was carried out as previously described [42]
using HRP-coupled secondary antibodies. Horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG and goat anti-mouse IgG secondary antibodies were obtained from
Jackson ImmunoResearch Laboratories. A SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific) electrochemiluminescence (ECL) kit was used according
to the manufacturer’s protocol to detect immune complexes, which were then visualized
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by autoradiography using Amersham Hyperfilm ECL film (GE Healthcare).

Protein

concentrations were determined according to Lowry [75].
Fluorescence microscopy
Cells were fixed on coverslips with 4% paraformaldehyde in PBS for 10 min and
then permeabilized for 5 min in 0.2% Triton X-100. Coverslips were blocked in PBS
with 0.2% Tween-20 (PBS/Tween) and 2% goat serum at room temperature for 1 hour.
Cells were then incubated in PBS/Tween with primary antibody (1:200) for 90 min at
ambient temperatures, followed by washing in PBS/Tween, and incubation with goat
anti-rabbit IgG or goat anti-mouse IgG antibodies conjugated to Alexa Fluor dyes (1:500
dilution in PBS/Tween for 60 min).

Cells were counterstained with 100 μM 4′-6-

diamidino-2-phenylindole (DAPI) for 2 min, rinsed, and mounted to microscope slides
with ProLong Antifade Mounting Kit (Molecular Probes).

Confocal microscopy was

performed at the Microscopy and Imaging Resources Laboratory at Wayne State
University, School of Medicine. Imaging was performed using a C-Apochromat 63x/1.2
WKorr water objective on either a Zeiss LSM 510 laser scanning microscope or an
Axioplan2 Imaging fluorescent microscope with Apotome imaging, or using a 63x/1.4 oil
objective on a Leica TCS SP5 laser scanning microscope. Laser scanning images were
acquired on a 1024 x 1024 pixel canvas with 8-line averaging. Apotome images were
obtained with a Zeiss Axiocam MRm B/W CCD camera.

Confocal images were

processed and optimized offline for publication using Photoshop (Adobe Systems Inc.).
Z-stack images created by the Leica TCS SP5 were compiled and optimized in ImageJ
(Wayne Rasband, National Institutes of Health). The ImageJ 3D Viewer plugin was
used to create three-dimensional z-stack images.
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RESULTS
CSQ-DsRed is localized to perinuclear regions of the cardiomyocyte
Following its overexpression in cultured adult rat cardiomyocytes, the fluorescent
fusion protein CSQ-DsRed produced a unique pattern of subcellular localization in
which both myonuclei were surrounded by intense red fluorescence (Fig. 12). Red
Figure 12.
Perinuclear
localization of CSQ-DsRed
in
cultured
adult
rat
cardiomyocytes.
(A)
Cultured primary adult rat
cardiomyocytes plated on
glass coverslips were treated
with Ad.CSQ-DsRed for 48 h,
and DsRed fluorescence was
analyzed
by
confocal
fluorescence
microscopy
after fixation.
(B) Cells
treated with Ad.CSQ-DsRed
(red) were stained with antiRyR2 antibodies (green).
Enlarged area (white box in
panel B) shows RyR2
immunostaining (C) or CSQDsRed fluorescence (D). (E)
a merge of C and D, shows
imperfect co-localization of
CSQ-DsRed and RyR2. (F)
Cells
co-infected
with
Ad.CSQ-DsRed (red) and
Ad.CSQ-HA (green) were
stained
with
anti-HA
antibodies. Bars, 20 µm
(panels A,B,F) or 2 µm
(panels C,D,E).
Imaging,
Apotome (panels A,F), Leica,
(panels B-E).

fluorescence could be visualized in most cells after 32 h of virus treatment, consistent
with levels of overexpression observed by immunoblotting (Fig. 13).

CSQ-DsRed

accumulated in cardiomyocytes to levels that were comparable to endogenous levels of
CSQ2 after 48 h, by which time CSQ-DsRed prominently surrounded both nuclei
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Figure 13. Immunoreactivity and specificity of anti-CSQ2, anti-DsRed, and antisec23 antibodies examined by immunoblotting as a function of CSQ-DsRed
overexpression. Following addition of Ad.CSQ-DsRed, cardiomyocytes were cultured
for indicated times (24-44 h). Cells prior to adenovirus treatment are shown as t = 0.
Cells were harvested in SDS-containing buffer and whole cell homogenates (equal
volumes from each cardiomyocyte dish, roughly 80 µg) were analyzed by SDS-PAGE
and immunoblotting. The nitrocellulose membrane was stained with amido black (Protein
stain), then probed with either anti-CSQ2 (t = 0, 24-40 h), anti-DsRed (t = 44 h), or antisec23 antibodies. Mobilities of molecular weight standards in kDa, left margin.

producing a pattern that was qualitatively similar for hundreds of cells examined. We
observed a very similar pattern of CSQ-DsRed localization in dishes of live (unfixed)
cultured cardiomyocytes (data not shown).

In addition to a very high level of red

fluorescence that appeared in close apposition to the nucleus, CSQ-DsRed could be
seen, albeit with much lower intensity, in perinuclear puncta. At these sites, the pattern
of CSQ-DsRed fluorescence was similar (Fig. 12C,D) but not identical (Fig. 12E) to
RyR2-positive immunofluorescence.

Peripheral CSQ-DsRed puncta became more

apparent with increasing time of virus treatment in culture, or when images were
brightened offline. In contrast to the peculiar CSQ-DsRed localization, the CSQ2-fusion
protein CSQ-HA was uniformly present in puncta throughout the cell, and never
exhibited the perinuclear enrichment observed using CSQ-DsRed (Fig. 12F).

This

suggested that the concentration of perinuclear CSQ-DsRed had resulted from the
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characteristic tetramerization of the DsRed portion of the fusion protein [76-77].
CSQ-DsRed around the nucleus co-localizes with rough ER markers
We hypothesized that the localization of CSQ-DsRed around the nucleus
represented its site of biosynthesis, that is, cardiac rough ER. To determine whether
markers of rough ER supported the juxtanuclear localization of cardiac rough ER, we
immunostained cultured cardiomyocytes with antibodies against components of the
protein biosynthesis and translocation machinery. TRAP is a major protein component
of the translocon in mammalian cells, where it is involved in nascent protein
translocation across the rough ER membrane [78]. Indirect immunofluorescence of the
subunit TRAPα in cultured cardiomyocytes expressing CSQ-DsRed strongly labeled the

Figure 14. Labeling of the cardiomyocyte rough ER using classic rough ER markers.
Cardiomyocytes were treated with CSQ-DsRed adenovirus for 48 h (red, A-C,E). AntiTRAPα images (green) were acquired from three optical planes starting from atop the
nucleus (A), and 2.2 µm (B) or 4.4 µm (C) below (bar, 20 µm). Panels 1-3 (TRAPα, CSQDsRed, merge, respectively) are enlargements of the leftmost nucleus of each cell shown in
A-C (bar, 2 µm). Transverse trafficking of CSQ-DsRed can be seen in the optical plane that
dissects the nuclear midline (B2, asterisk) but appears as distinct cisternae in an adjacent
optical slice (C2, double asterisk). Anti-TRAM immunofluorescence (green) was imaged in
cardiomyocytes not treated with Ad.CSQ-DsRed, but immunostained with ant-RyR (red): D1,
rightmost nucleus in panel D. Bar, 2 µm. (E) anti-ribosomal S6 protein immunofluorescence
(green) was imaged in cells overexpressing CSQ-DsRed (red). Bar, 2 µm. Imaging, Leica
(panels A-D), Zeiss LSM (panel E). (F) immunoblot analysis of rat and dog heart
homogenates (H, 100 µg) and microsomal vesicles (MV, 50 µg) using anti-TRAPα
antibodies. Mobilities of molecular weight standards in kDa, left margin.
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myocyte perinuclear region, co-localizing with CSQ-DsRed fluorescence (Fig. 14A-C).
Levels of anti-TRAPα immunofluorescence were highest in cisternae closely apposed to
the nucleus, whereas CSQ-DsRed could be seen in selected optical slices to extending
beyond to successive cisternae (panel C2, double asterisk). A single optical slice was
sometimes able to capture transverse trafficking as a continuous CSQ-DsRed
fluorescence between the perinuclear region and an adjacent cisterna (panel B2,
asterisk). The abundance of TRAPα in cardiomyocyte membranes was also evident by
immunoblotting, where it appeared as a single immunoreactive protein band of roughly
34 kDa [79] enriched in microsomes prepared from either rat or canine heart tissue (Fig.
14F). Further support for the idea that the perinuclear region could be a major site of
protein synthesis in cardiomyocytes came from localization of the translocon accessory
protein TRAM [80] and the ribosomal S6 protein (Fig. 14D,E respectively) to areas
surrounding the myonucleus.
Transport of proteins from the rough ER in mammalian cells is associated with
the formation of ER exit sites that become COPII transport vesicles [81-83]. Because
fluorescence microscopy of CSQ-DsRed suggested a relatively direct transport step
between its apparent site of biosynthesis (perinuclear rough ER) and adjacent junctional
SR puncta, we asked whether ER exit site location might also reflect such transport in
cardiomyocytes.

Sec23 is a well-characterized marker of ER exit sites and COPII

vesicles in mammalian cells [84].

In untreated cardiomyocytes, sec23 produced a

pattern of immunostaining along Z-lines that was interspersed with RyR2-positive
staining (Fig. 15A and inset). This suggested that sec23 might be bound to membrane
surfaces of cisternae along Z-lines. When sec23 localization was analyzed in cells
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overexpressing CSQ-DsRed, sec23 appeared to be bound to the perinuclear membrane
compartment enriched in CSQ-DsRed (Fig.15B). Because CSQ-DsRed is expected to
be an intralumenal ER protein whereas sec23 is a cytosolic protein, such interactions
could not theoretically be direct, and would presumably require a transmembrane signal
resulting from enhanced levels of lumenal CSQ-DsRed.

The reason for this

unexplained translocation of sec23 was not further investigated, but could reflect the
inefficient ER exit of CSQ-DsRed.

Sec23 levels measured by immunoblotting and

densitometry exhibited
a

roughly

decrease

in

25%
cells

treated with Ad.CSQDsRed, but showed no
further changes with
time

of

treatment

adenoviral
(Fig.

13,

rightmost panel).
Direct

CSQ-DsRed

fluorescence

is

distinct from indirect
CSQ-DsRed
immunofluorescence

Figure 15. Sec23 subcellular localization in cultured rat
cardiomyocytes.
(A) cultured rat cardiomyocytes were
immunostained using anti-sec23 antibodies (green), and antiRyR2 antibodies (red, shown only in inset). Inset, sec23, RyR2,
and merge (top to bottom) of representative Z-lines. (B) cultured
cardiomyocytes were treated with Ad.CSQ-DsRed (red) for 48 h.
Red (CSQ-DsRed) and green (sec23 immunofluorescence)
channels are shown superimposed. Bar, 20 µm. Images, Leica
TCS SP5.

Although CSQ-DsRed was readily detected on immunoblots using either antiDsRed or anti-CSQ2 antibodies (Fig. 13), we were surprised to find that after 48 h of
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DsRed overexpression, neither anti-DsRed nor anti-CSQ2 antibodies were able to
detect CSQ-DsRed in the perinuclear compartments of fixed cardiomyocytes (Figs. 1618).

Instead, anti-DsRed and anti-CSQ2 antibodies prominently labeled the cell

periphery.

This result was seen with three separate antibodies to the CSQ-DsRed

fusion protein (Fig. 17C, 17D, and 18F).
As discussed below, a likely explanation for the loss of immunoreactivity was that
interaction of antibodies was lost due to the (predicted) tetrameric structure of DsRed
[76-77].

This did lead, however, to a labeling of two separate pools of overexpressed

CSQ-DsRed having alternate subcellular distributions. As supported in experiments
Figure 16.
CSQ-DsRed fluorescence
versus anti-DsRed immunofluorescence.
Cardiomyocytes were treated with CSQDsRed adenovirus for 48 h, then fixed and
stained
with
anti-DsRed
antibodies.
Confocal fluorescent images were obtained
(z-stack consisting of 38 x 0.5 µm optical
slices) on the Leica TCS SP5; selected
slices are shown (z = 2.5, 3.5, 5.0, 8.0, 9.5
µm for panels A, B, C, D and E,
respectively).
CSQ-DsRed fluorescence
(red) and indirect anti-DsRed (green)
fluorescence are shown together in all
panels (bar, 10 µm). The entire Z-stack was
assembled into a three-dimensional image
using the ImageJ 3D Viewer plugin in
conjunction with ImageJ software, and
cropped at the first nucleus in order to
highlight the radial distribution and
separation of CSQ-DsRed tetramers (red)
and monomers (green) (panel F).
An
enlargement of the boxed area in E (panel
G), representing a peripheral slice of the
cardiomyocyte, shows the presence of
CSQ-DsRed
tetramer
largely
in
compartments distinct from the monomer
(bar, 1 µm). The boxed area in G was also
enlarged (panel H) to show noncolocalization occurring even at the
sarcomeric level, where it appears that
CSQ-DsRed tetramers redirect into free-SR
rete. Bar, 0.5 µm.
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below, and discussed in later sections, we interpreted the red and green labeling as
tetrameric CSQ-DsRed and an immunoreactive CSQ-DsRed monomer, respectively.
The perinuclear versus peripheral (tetrameric versus monomeric) staining patterns were
seen in sequential optical slices (z-stack), validating a 3-dimensional distribution of the
direct DsRed fluorescence near the nucleus (Fig. 16A-E). Indeed, the radial nature of
the direct DsRed fluorescence was apparent in virtual transverse slices of the
reconstructed z-stack along its longitudinal length (Fig. 16F). Closer examination of an
optical

slice

(panel

G)

near

the

cell

periphery

(panel

E)

where

green

immunofluorescence (CSQ-DsRed monomers) dominates direct red fluorescence
(CSQ-DsRed tetramer), revealed an imperfect co-localization of the two forms. Higher
magnification of the two fluorescent signals confirmed minor differences in distribution at
the level of individual sarcomeric SR structure (panel H). Even where indirect and direct
CSQ-DsRed fluorescence signals occurred together, a distinct distribution was revealed
for each, perhaps suggesting that CSQ-DsRed tetramers and monomers traffic
differently.
To further analyze the relationship between CSQ-DsRed fluorescence and its
immunoreactive forms, we examined a time course of overexpression by confocal
fluorescence microscopy.

Whereas CSQ-DsRed fluorescence did not develop until

about 32 h of adenovirus treatment, anti-DsRed and anti-CSQ immunofluorescence
were both detected after only 16-20 h, appearing around nuclei (Figs. 17,18). Timedependent changes in CSQ-DsRed fluorescence and immunofluorescence were
consistent with its translation and accumulation in perinuclear rough ER after 16 h,
followed by its increasing concentration in the same region as a red fluorescent
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polymer. Once juxtanuclear polymerization occurred, CSQ-DsRed, already in junctional
SR, continued its anterograde movement towards the cell periphery where it appeared
to concentrate by 48 h as (green) monomer.

The fact that this movement of

immunofluorescent CSQ-DsRed could be visualized suggested that additional CSQDsRed was not being generated along the rough ER-junctional SR pathway, perhaps
Figure 17.
Time-dependent
changes
in
anti-CSQ2
immunofluorescence
during
CSQ-DsRed overexpression.
Cardiomyocytes
were
left
untreated (A), or treated with
CSQ-DsRed adenovirus for 20 h
(B) or 48 h (C,D) before fixation
and pemeabilization. Fixed cells
were
immunostained
with
monoclonal
anti-CSQ2
antibodies (green) (A-C) or rabbit
polyclonal anti-CSQ2 antibodies
(D), and analyzed for red DsRed
fluorescence
and
green
immunofluorescence using laser
confocal microscopy (Leica TCS
SP5). The inset in panel B
shows a portion of the cell which
is brightened offline so that
fluorescence of endogenous
native rat CSQ2 is similar in
panels A and B. Bar, 20 µm.

because all CSQ-DsRed monomer was scavenged within the perinuclear region by the
polymer.
The fluorescence staining pattern of native rat CSQ2 could be seen in untreated
(control) heart cells exhibiting a steady-state distribution characteristic of junctional SR
puncta (Fig. 17A). Visualization of native rat CSQ2, however, required fluorescence
acquisition times that produced overexposures of CSQ-DsRed immunofluorescence
(Fig. 17B, inset), so was not visible with the exposure times used in subsequent figures.
In contrast to the relatively unchanging pattern of native CSQ2 over a 48 h time course
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(not shown), overexpressed CSQ-DsRed immunofluorescence exhibited a timedependent
trafficking.
To
summarize, our
data

suggest

that

the

tetrameric form
of CSQ-DsRed,
while necessary
to produce the
intense

red

fluorescence,
was

relatively

Figure 18. Time-dependent changes in CSQ-DsRed fluorescence
and anti-DsRed immunofluorescence. Cardiomyocytes were left
untreated (A), or treated with CSQ-DsRed adenovirus for 16 h (B), 20 h
(C), 24 h (D), 36 h (E), or 48 h (F) before fixation and permeabilization.
Fixed cells were immunostained with anti-DsRed antibodies (green), and
analyzed for red DsRed direct fluorescence and green indirect
immunofluorescence using laser confocal microscopy (Leica TCS SP5).
Bar, 10 µm. Magnifications among panels are similar but may vary
slightly to better illustrate structural differences.

incapable of interaction with antibody molecules. Meanwhile, antibodies to either half of
the fusion protein detected CSQ-DsRed monomers which exhibit highly reduced, if any,
intrinsic (direct) fluorescence. The data indicate that once CSQ-DsRed tetramerizes
within rough ER, its anterograde trafficking is very substantially restricted, whereas
molecules that do not incorporate into the polymer within the nuclear envelope, populate
increasingly peripheral junctional SR sites. Based upon these new studies on CSQ2
trafficking from rough ER to junctional SR compartments, and our recent work on
polymer-dependent trafficking of CSQ2 in nonmuscle cells [23, 71], we propose a new
model of CSQ2 trafficking and junctional SR biology in the adult cardiomyocyte.
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DISCUSSION
In nonmuscle cells, we previously concluded that CSQ2 is retained within specific
secretory compartments by virtue of its polymerization [23, 71].

CSQ2 polymers

accumulate in discrete secretory compartments presumably because soluble protein
cargo integration into COPII vesicles is very inefficient for large polymers [71, 85-86]. In
nonmuscle cells, cardiac CSQ polymers form in an early ER compartment comprised of
polygonal cisternae throughout the cell, but are absent from the ERGIC [23]. This
subcellular localization for CSQ2 is also reflected in the structure of its N-linked glycan,
which is always found in an unprocessed form (GlcNAc2Man9,8).
Skeletal muscle CSQ localizes not to ER, but exclusively to the intermediate
compartment (ERGIC) of nonmuscle cells [71]. The remarkable difference between
localization of these two CSQ isoforms within the same cell type underscores the
relationship between polymerization and localization in mammalian cells. Thus, not only
can CSQ polymerize in vivo, but differences in milieu that exist within lumens of two
consecutive and juxtaposed subcompartments (ER and ERGIC) are sufficient to
completely discriminate and segregate these two forms of CSQ. Differences in the
glycan structures on a conserved Asn316 in the two proteins are also consistent with the
differential localization [71].
Tetramerization of DsRed is a documented aspect of its structure [76-77]; in fact,
DsRed fluorescence is thought to require its tetramerization, although a monomeric
form exhibiting greatly reduced fluorescence has been generated through numerous
point mutations [77]. Thus, when fused with CSQ2, tetramerization of DsRed led to its
effective retention, probably because of inefficient anterograde trafficking, similar to that
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reported for cardiac CSQ polymers in nonmuscle cells [23, 71]. It is also possible that
CSQ-DsRed tetramers led to even more complex polymers as a result of finite levels of
CSQ2 polymerization that might occur even in the perinuclear region, although native
CSQ2 does not typically accumulate (polymerize) in this compartment.
Anti-DsRed fluorescence and CSQ-DsRed immunofluorescence were mutually
exclusive because DsRed tetramerization simultaneously produces a bright red
fluorescence [77] while effectively turning off antibody detection.

This generated

separate assays for polymeric versus monomeric protein molecules that exhibited
distinct patterns of intracellular trafficking.

Time-dependent features of the

overexpression of CSQ-DsRed were particularly revealing. CSQ-DsRed was initially
detectable only by immunoreactivity, where it had a juxtanuclear localization. At longer
times, immunoreactive perinuclear CSQ-DsRed was replaced with the bright red
fluorescence expected for DsRed tetramers in the same compartment.

However,

whereas immunoreactive (monomeric) CSQ2 trafficked out of the perinuclear region,
albeit slowly (Figs. 17,18), the red fluorescent tetramer was too large to traffic to
junctional SR puncta to any significant extent [71, 85-86].
By the end of a 48 h incubation period, the entire immunoreactive pool of CSQ2
was concentrated at the cell periphery (Fig. 16F).

If immunoreactive CSQ-DsRed

represents monomeric CSQ-DsRed, then the shift of this pool of protein from the
perinuclear region to the cell periphery suggests that the input of additional
immunoreactive CSQ-DsRed protein molecules was no longer occurring. This may be
directly due to the scavenging of all newly synthesized CSQ-DsRed within the
fluorescent polymer within the perinuclear region once formed. Thus, without further
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input of newly-synthesized CSQ-DsRed, the "pulse" of monomeric CSQ-DsRed that
escaped juxtanuclear polymerization could be visualized as it moved through the full
extent of the Z-line localized ER/SR pathway.

The fate of this CSQ-DsRed that

concentrated in the cell periphery after 48 h was not investigated in this study, but
represents an interesting question for future studies.
Protein markers of the ER translocon complex, TRAPα and TRAM, also had a
juxtanuclear localization in the cardiomyocyte, suggesting that this is a major site of
rough ER and CSQ2 biosynthesis. Rough ER was previously visualized by electron
microscopy in a continuum with the nuclear membrane, as one of a few
morphologically-defined sites within adult rabbit cardiomyocytes [87].

Translation

around myonuclei in cardiomyocytes for specific cardiac proteins has not been reported
to our knowledge, but has been discussed as one of at least two such sites in skeletal
muscle myocytes [88].
CSQ-DsRed fluorescence could be observed connecting the perinuclear region
directly to adjacent junctional SR (RyR2-positive) puncta in optical sections that
bisected the myonuclear midline (Figs. 12E, 14B2, asterisk).

A pathway for SR

membrane protein trafficking along Z-lines has not previously been reported in
cardiomyocytes, but may be similar to the exporting ER network described by Kaisto
and Metsikkö in rat skeletal muscle myofibers [89].

We also observed apparent

longitudinal trafficking of CSQ-DsRed, particularly when CSQ-DsRed-containing
cisternae were viewed near the outer edges of the cell (Fig.16E,G,H). A mechanism of
longitudinal trafficking of CSQ2 is also not known, but our data for sec23, a microtubulebased trafficking protein of COPII vesicles [84], suggests that junctional SR to
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longitudinal SR might represent the normal direction of protein trafficking in the cardiac
secretory pathway. Free SR is enriched in proteins that contain the C-terminal KDEL
retrieval sequence [90-92]. Because KDEL proteins are thought to be enriched in both
ER and ERGIC [23, 93], their presence is consistent with free SR being a subcellular
compartment distal to junctional SR. The view of junctional SR as equivalent to ER,
and longitudinal (or free) SR as being equivalent to the intermediate (ERGIC)
compartment is consistent with studies from the Metsikkö laboratory in skeletal muscle
myofibers [89, 94]. Similar to the limited accumulation of CSQ-DsRed in longitudinal SR
(Fig. 16H), native CSQ2 that escapes retention by polymerization should also traverse
this part of the cardiac secretory pathway, as do the other muscle-specific luminal
ER/SR Ca2+-binding proteins sarcalumenin and histidine-rich Ca2+-binding protein [17].
In a new model of CSQ2 biosynthesis and trafficking in cardiomyocytes (Fig. 19), we
propose that CSQ2 is synthesized at sites within the nuclear envelope, and then traffics
directly to junctional SR in the direction of the cell surface. In the case of CSQ-DsRed,
polymers (tetramers) are retained in rough ER and traffic slowly towards distal junctional
SR only as tetramers dissociate to monomers. We infer from these data that CSQ2
normally polymerizes only within junctional SR puncta, a process that prevents or slows
its anterograde trafficking, and presumably its secretion. We conclude therefore, that,
as in the case of mammalian nonmuscle cells, CSQ2 polymerizes in junctional SR
because it is the first intracellular compartment that satisfies the biophysical criteria for
polymerization.
The model presented here may help to explain previously reported CSQ2 protein
structures in normal and hypertrophied hearts from small dogs [35]. In beagle heart
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Figure 19.
Model of
Figure 19
native CSQ2 trafficking
from
rough
ER
to
junctional
SR
in
cardiomyocytes.
(A)
Native CSQ2 exists as
monomers
or
linear
polymers
in
dynamic
equilibrium
inside
the
secretory
pathway
of
cardiomyocytes.
While
monomeric CSQ2 traffics
anterogradely, polymeric
CSQ2 cannot, leading to
its
accumulation
in
junctional
SR
puncta.
CSQ-DsRed, in contrast to
native CSQ2, polymerizes
and accumulates in rough
ER around nuclei. CSQDsRed monomers, like
CSQ2 monomers, can
traffic anterogradely where
they can be specifically
detected by antibodies
against either half of the
fusion protein pair. Not
shown in this scheme are
forms
of
CSQ2
in
junctional SR that might
contain CSQ-DsRed linear
homopolymers
and
heteropolymers
(with
native CSQ2).
(B) In
cardiomyocytes,
native
CSQ2 is synthesized in
perinuclear rough ER.
Trafficking
proceeds
across a direct cellular transport pathway (large arrow) to perinuclear junctional SR, dependent
on a dynamic polymer (P)-monomer (M) equilibrium. A predominance of native CSQ2
monomers in rough ER and along the rough ER-junctional SR trafficking pathway led to
anterograde trafficking. CSQ2 polymers form within junctional SR puncta due to its distinctive
intraluminal ionic conditions, leading to its accumulation [71]. ER-exit sites along this same ER
pathway (highlighted by sec23 immunostaining, cf. Fig. 15), may separate the basic cardiac ER
(junctional SR) from an intermediate compartment (longitudinal SR) that traffics along myofibrils
(smaller arrows). In the case of CSQ-DsRed overexpression in cardiomyocytes, tetrameric
CSQ-DsRed accumulates in rough ER. Protein monomers of CSQ-DsRed predominantly traffic
anterogradely to accumulate in peripheral junctional SR puncta. Puncta in close proximity to
cardiomyocyte nuclei may contain the inositol trisphosphate (IP3) receptor in addition to, or
instead of the more prominent ryanodine receptor contained in more peripheral junctional SR
puncta [95].
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tissue, CSQ2 molecules can be divided into two types based upon their glycan
structures. Most CSQ2 glycans show extensive mannose trimming (Man3-5), indicative
of junctional SR localization [31, 34], but a minor portion of CSQ2 contains glycans
indicative of rough ER localization (Man8,9) [23, 31]. This rough ER portion of CSQ2
doubles in rapid-pacing induced heart failure, as does its state of phosphorylation [35].
Moreover, ER forms of CSQ2 (Man9,8) in heart are fully phosphorylated, whereas
junctional SR forms of CSQ2 (Man 3-6) are increasingly dephosphorylated [34].
Phosphorylation by protein kinase CK2 may thus be responsible for its rough ER
retention.
CONCLUSIONS
In summary, CSQ-DsRed fluorescence and immunofluorescence reveal several
new aspects of CSQ biology by essentially slowing down its secretion, and by causing it
to polymerize in a proximal compartment (rough ER).

Our new findings and

accompanying model include: 1) the identification of the subcellular site of CSQ2
biosynthesis (cardiac rough ER), 2) demonstration of a CSQ2 polymerization-dependent
compartmentalization in cardiomyocytes, 3) the suggestion that CSQ-DsRed traffics
directly from rough ER to junctional SR along a novel, albeit uncharacterized
intracellular pathway, and 4) the characterization of rough ER and junctional SR as
cardiac ER, and longitudinal SR as a compartment distal to ER exit sites possibly
corresponding to ERGIC. These data and model may aid in understanding the changes
in CSQ2 and SR biology associated with new transgenic models and in diseases
associated with inner membrane biology in adult cardiomyocytes.
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CHAPTER 3
IDENTIFICATION OF CARDIAC CALSEQUESTRIN KINASE AND THE EFFECTS OF
C-TERMINAL PHOSPHORYLATION
ABSTRACT
The luminal SR protein CSQ2 contains phosphate on roughly half of the
serines found in its short cardiac-specific C-terminus.

The sequence around the

phosphorylation sites in CSQ2 suggest that the in vivo CSQ2 kinase is protein kinase
CK2, even though this enzyme is thought to be present only in the cytoplasm and
nucleus.

To test whether CSQ2 kinase is protein kinase CK2, we combined

experimental approaches directed at reducing the effects of CSQ2 phosphorylation in
intact cells. In vitro, tetrabromocinnamic acid (TBCA, 100 µM) inhibited both CSQ2
kinase and CK2 activities by about 85% over the same range of concentrations. In
intact cultured primary adult rat cardiomyocytes and in COS cells, 24 h of TBCA (100
µM) treatment produced a roughly 75% decrease in phosphorylation of CSQ2.

To

further validate the identity of CSQ2 kinase as protein kinase CK2, we down-regulated
both CK2α subunits in COS cells by transfection of appropriate siRNA, producing an 8590% decrease in CK2α and CK2α′ protein levels. CK2-silenced cells exhibited a twofold reduction in CSQ2 kinase activity.

Endogenous CSQ2 overexpressed in CK2-

silenced COS cells was also reduced by a factor of two. These pharmacologic and
biochemical data suggest that CSQ2 in intact cells is phosphorylated by CK2, a
cytosolic kinase (CK2) that could phosphorylate CSQ2 only during or before nascent
protein translocation. When CSQ2 phosphorylation site mutants were analyzed in COS
cells, the characteristic rough ER form of the CSQ2 glycan (GlcNAc2Man9,8)

42

underwent phosphorylation-site dependent processing such that CSQ2-nonPP (Ser to
Ala mutant) and CSQ2-mimPP (Ser to Glu mutant) produced apparent lower and
greater levels of ER retention, respectively.

Taken together, our data support a

hypothesis in which CK2 is able to phosphorylate CSQ2 co-translationally at
biosynthetic sites in rough ER, a process that results in changes in its subsequent
movements through the secretory pathway.
INTRODUCTION
Calsequestrin is a resident luminal protein of the SR [11, 19-20, 22, 33, 96]
where an involvement in junctional Ca2+ release is assumed to be its primary function
[13, 30]. The fast-twitch skeletal muscle CSQ1 and cardiac CSQ2 isoforms come from
independent genes but share a relatively conserved sequence [33, 97]. Mammalian
CSQ2 proteins have an 18-25 residue C-terminal extension that contains multiple
serines in an otherwise highly acidic sequence, and is not present in CSQ1 [33, 98].
These C-terminal serines are prolific in vitro substrates for an endogenous protein
kinase, making CSQ2 by far the most heavily phosphorylated protein in heart cell
homogenates, in the absence of exogenous kinase activators such as cyclic AMP [34].
It is similarly phosphorylated in all mammalian cells following its overexpression [23, 31,
34].
Both CSQ2 phosphorylation state and Asn(N)-linked glycan structure can be
simultaneously determined by mass spectrometric analysis of purified CSQ2 protein
[31, 35].

From these analyses, a great deal of information about the relationship

between CSQ2 phosphorylation and its trafficking has been obtained. For example,
pathways of CSQ2 trafficking are revealed in the CSQ2 glycan structures, and it
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appears clear that no CSQ2 in heart or nonmuscle cells ever leaves ER compartments.
The CSQ2 glycan is comprised of only high-mannose structures GlcNA2ManN, where N
= 3-9 depending upon the extent of mannose trimming [31, 34-35]. Recently, we have
described novel ER-to-SR intracellular trafficking pathways in the adult cardiomyocyte,
concluding that junctional SR represents bona fide ER. CSQ2 traffics directly from
juxtanuclear rough ER to junctional SR where it is retained by its polymerization [99].
Mannose trimming accompanies its anterograde trafficking in nonmuscle cells, whereas
it is a hallmark of its rough ER to junctional SR trafficking in cardiac myocytes [23, 31,
34]. We have also hypothesized that the longitudinal SR corresponds to the
intermediate compartment (ERGIC), requiring proteins such as SERCA2a to enter ER
exit sites that lie along the junctional SR pathway [99].
Mass spectrometry of intact purified CSQ2 also reveals significant insights into its
phosphorylation.

When analyzed from heart tissue, newly synthesized molecules

(having unprocessed glycans (Man9,8)) are found to exist only in the completely
phosphorylated state [34]. Conversely, as CSQ2 undergoes mannose trimming in its
trafficking to junctional SR, the number of unphosphorylated molecules dramatically
increases, such that the most highly trimmed glycans contain no phosphate [34]. When
analyzed in cultured nonmuscle cells, it is also evident that anterograde trafficking is
also accompanied by CSQ2 dephosphorylation [23, 31, 34].
Despite considerable knowledge about the CSQ2 phosphorylation reaction in
nonmuscle cells and cardiac myocytes, the identity of the CSQ2 kinase has not yet
been established. There are no known luminal serine/threonine kinases identified in the
literature, to our knowledge, that could serve as a candidate CSQ2 kinase in vivo. The
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putative identity of CSQ2 kinase derives from the fact that its C-terminal
phosphorylation sites (Table 2) matches closely a consensus sequence (S/T-X-X-D/E)
for the cytosolic serine/threonine protein kinase CK2 (formerly casein kinase 2) [37-38].
CSQ2 is also a very efficient in vitro substrate for CK2 [34, 36].
A paradox, however, results if one assumes that CK2 is the CSQ2 kinase, as
CK2 has no signal sequence for gaining access to the ER lumen [100], whereas CSQ2
is thought to be wholly contained within the SR lumen throughout its lifetime [12, 33].
One hypothetical mechanism for reconciling the lack of co-localization with a cotranslational phosphorylation event would be that CSQ2 phosphorylation occurs prior to
nascent polypeptide translocation across the rough ER membrane [64].
Mammalian protein kinase CK2, in the holoenzyme form, is composed of two
separate catalytic subunits and two identical regulatory subunits [101]. The catalytic
subunits, CK2α and CK2α′, share approximately 90% homology and are the product of
different genes [44, 102-103]. Both catalytic subunits are capable of phosphorylating
substrates independent of holoenzyme formation, and have been localized to different
areas of the cell [101, 104-105]. CK2 has been shown to promote cell proliferation
[106], and has recently become a chemotherapeutic target in order to promote tumor
regression [107] leading to the advent of a series of new and highly specific inhibitors
[61].
In this study, we have combined cellular and molecular approaches to investigate
the actions of protein kinase CK2 on the cardiac-specific C-terminus of CSQ2.
Reduced CSQ2 phosphorylation produced by reversible CK2-specific inhibitors, loss of
CK2 protein by siRNA, and loss of phosphorylation by sequence mutations all support a
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hypothesis in which phosphorylation of CSQ2 by the cytosolic protein kinase CK2
occurs co-translocationally in rough ER to affect subsequent anterograde trafficking.
MATERIALS AND METHODS
Antibodies and commercial proteins
Monoclonal antibody specific to CSQ2 was the generous gift of Dr. Larry Jones,
Indiana University School of Medicine. Mouse monoclonal antibody raised to human
protein kinase CK2α catalytic subunit (CSNK2A1) and rabbit polyclonal antibody raised
to human protein kinase CK2α′ catalytic subunit (CSNK2A2) were purchased from
Abcam (ab70774 and ab10474). Human CSNK2A1 (His-tagged CK2α) and CSNK2A2
(GST-tagged CK2α′) recombinant proteins were purchased from Invitrogen (PV3248
and PV3624).
Cell culture
COS-7 African green monkey kidney (COS) and human embryonic kidney 293
cells (HEK-293), purchased from American Type Culture Collection, were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM HEPES, pH 7.4, 10%
fetal bovine serum, 100 units/ml penicillin G, 0.1 mg/ml streptomycin and 0.25 μg/ml
amphotericin B, at 37 °C with 5% CO2.
Cardiomyocyte preparation
Rat ventricular cells were enzymatically dissociated using a Langendorff
perfusion apparatus, as previously described [99]. Heart cells were cultured on laminincoated dishes in modified Medium 199 containing 2% bovine serum.
concentrations were determined according to Lowry et al. [108].

Protein
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CSQ2 plasmid and adenoviral constructs
CSQ2 constructs and viral inserts were generated from wild type canine cardiac
CSQ2 cDNA [33]. Creation and purification of adenoviruses for wild-type CSQ2
(Ad.CSQ) and the non-phosphorylatable mutant Ad.nonPP (Ser 378,382,386 Ala) were
previously described [31]. The phosphorylation mimic CSQ2 mutant Ad.mimPP was
produced in an identical manner to that of Ad.nonPP except glutamates were used to
replace the C-terminal serines (Ser 378,382,386 Glu). Briefly, the mutating reverse
primer (67-mer) contained 3 single base changes necessary for the Ser to Glu
conversion. PCR products were cloned into pBluescript (Stratagene), sequenced by the
dideoxy method [109], and then subcloned into the pShuttle plasmid for virus
construction (AdEasy System, American Type Culture Collection).
Adenovirus-mediated overexpression
Cells were treated with recombinant adenoviruses at a multiplicity of infection
(MOI, pfu/cell) of 50 or 100 for COS and heart cells [31]. Purified viruses were added to
cultured cells at the time of plating and left on throughout the overexpression period.
Purification of overexpressed CSQ2
Purification of CSQ2 from COS and cardiomyocyte cultures was carried out two
days post-infection, as previously described [31] but with minor modifications.

Cell

pellets were resuspended at roughly 1 mg/ml in extraction buffer containing 10 mM Tris,
pH 8.0, 250 mM NaCl, 1% Triton X-100 and 1 mM EGTA. Extracts were centrifuged at
25,000 x g for 30 min, bound to 40 µl DEAE-Sephacel (Amersham Biosciences),
washed, then eluted with 100 µl extraction buffer containing 500 mM NaCl. SDS-PAGE
analysis was carried out according to Laemmli [74].
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Preparation of native CSQ2 kinase sources
Freshly isolated adult rat cardiomyocytes and cultured COS cells were pelleted
and washed in PBS.

The pellets were resuspended in low ionic strength media

containing 5 mM MOPS, pH 8.0, 1 mM EGTA and protease inhibition cocktail (Sigma
P8340). Suspensions were incubated on ice for 10 min and then passed through a
255/8 ga. needle and glass/teflon homogenizer 10 times each. NaCl was added to the
resulting lysates (homogenates) to a concentration of 100 mM. Detergent mixtures
were created by adding Triton X-100 to the homogenates to a final concentration of 1%.
Identical volumes (0.5 ml) of homogenates, detergent-free and detergent extraction
mixtures were subjected to high speed centrifugation (30,000 x gmax for 15 min) in order
to obtain homogenates and extracts.
In vitro phosphorylation of purified CSQ2
The standard CSQ2 phosphorylation reaction mixture for “back phosphorylation”
consisted of 20 mM MOPS, pH 8.0, 150 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, and
contained 20 µM [γ -32P]ATP (3000 cpm/pmol), 2 μg purified CSQ2 substrate, and a
source of CSQ2 kinase, brought to a total volume of 50 µl with distilled water. As a
CSQ2 kinase source, either 2 μg of COS cell or cardiomyocyte homogenate or
detergent extract was used, as indicated; or 0.1-0.4 µg purified human CK2α or CK2α'
kinase was added as indicated.

Quantification of phosphate incorporation was

determined by SDS-PAGE, autoradiography, and scintillation counting of radioactive
bands excised from dried gels.

Measurements of “front phosphorylation”, or

endogenous phosphorylation, included a pretreatment with or without 0.01 U acid
phosphatase (P0157, Sigma) for 60 min in 10 µl of 30 mM MES buffer, pH 5.8, 0.1 mM
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EGTA, as previously described [36], then dilution into phosphorylation buffer to a final
volume of 50 µl. For comparison with CK2α' commercial protein kinase activities, 2 µg
of CSQ2 was used as substrate and equal units of kinase were compared: CK2α was
0.5 U/µg, CK2α' was 0.25 U/µg (1 U = nmol Pi /mol RRRDDDSDDD peptide/min).
Inhibition of CSQ2 kinase using specific inhibitors of protein kinase CK2
The CK2 specific inhibitors tetrabromocinnamic acid (TBCA, Calbiochem), 2dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, Calbiochem) and 4,5,6,7tetrabromobenzotriazole (TBB, Sigma) were dissolved in DMSO then diluted into
phosphorylation reactions to varying micromolar concentrations to establish which was
the most potent and gave the most consistent results. To inhibit CSQ2 phosphorylation
in intact cells, COS or heart cells were plated in 6-well dishes with Ad.CSQ for 24 h.
TBCA (100 µM) or DMSO was then added for a total incubation time of 48 h, then cells
were harvested for analysis.
Mass spectrometry
For

mass

spectrometry

of

CSQ-WT,

CSQ-nonPP,

and

CSQ-mimPP,

recombinant proteins were produced in HEK cells following the addition of respective
viruses. CSQ2 was purified and prepared for electrospray ionization mass spectrometry
as previously described [23].
RNAi
HEK and COS cells were grown in 100 mm culture dishes for 24 hrs with or
without Ad.CSQ or Ad.nPP, then transfected using DharmaFECT 1 transfection
Reagent (Thermo Scientific T-2001-01), for 48 h with 100 nM Dicer-Substrate RNAi
(DsiRNA, IDT), designed to silence either CSNK2A1 (IDT #HSC.RNAI.N177559.10.3),
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CSNK2A2 (IDT #HSC.RNAI.N001896.10.2), or a combination of both.

Negative

controls included no siRNA or DS NC1 universal DsiRNA negative control (IDT).
Detergent extracts were created for use with standard back and front phosphorylation
assays described above, after normalization by protein assay.
mRNA analysis
RNA extraction from COS cells overexpressing Ad.CSQ was performed using
RNeasy Fibrous Tissue Mini Kit (Qiagen) according to manufacturer’s protocol. RNA
concentrations were determined by spectrophotometer at 260 nm. One microgram of
DNase-treated total RNA was reverse transcribed using a high-capacity cDNA reverse
transcription kit (Applied Biosystems).

Quantitative real-time PCR (qPCR) with fast

SYBR green (Applied Biosystems Step One with v2.0 software) was performed using
CSQ2 primers designed to span one intron. Relative quantitation was then used to
evaluate mRNA levels compared to GAPDH internal control. Canine CSQ2 forward
primer: 5′- CCA AGC TTG CCA AGA AGC TGG GT -3′, reverse primer: 5′- ACG TCA
GCT GCA AAC TCG CCA -3′.
RESULTS
Optimization of CSQ2 phosphorylation assays
Native and overexpressed canine CSQ2 is phosphorylated in heart or nonmuscle
cells on the same sites, and the reactions are assumed to occur by a similar CSQ2
kinase associated in some way with the ER [31, 34]. We analyzed CSQ2 kinase activity
from both primary rat cardiomyocytes and COS cells.

Both cell types were

homogenized in the presence of Triton X-100 detergent to make CSQ2 kinase available
to phosphorylate purified canine CSQ2 in vitro. Determinations of reaction linearity as a
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Figure 20. Effects of cellular protein on CSQ2 kinase activity. (A) increasing
concentrations, 1, 2, 5, 10, 20, 30 or 50 µg of rat heart cell detergent extract or COS cell
homogenate was used to phosphorylate 2 µg of purified native canine CSQ2
(arrowheads). Reaction mixtures were analyzed by SDS-PAGE (MW markers, 66 and 43
kDa) and [32P]autoradiography.
(B) radioactive incorporation was determined, and
kinase activity is shown on the y-axis. (C,D) CSQ2 kinase activity was measured in 2, 5
or 20 µg of homogenate, from a mild-detergent extraction of 2, 5 or 20 µg of homogenate,
or from a detergent-free extraction of 2, 5 or 20 µg of homogenate derived from
cardiomyocytes (C) or COS cells (D). Inset, immunoblot of CK2α or CK2α' subunits from
50 µg of COS cell homogenate (H), detergent extract (DE), or detergent-free extract
(DFE).

function of protein (kinase source) were carried out with varying amounts of
homogenate protein. In contrast to an expected linear relationship between protein and
kinase activity, increasing protein concentration actually exhibited an inverse
relationship with CSQ2 phosphorylation (Fig. 20A,B); that is, increasing homogenate
protein produced decreasing levels of [32P]-phosphate incorporation. To remedy this
extreme nonlinearity, we tested whether linearity could be better achieved using either a
mild detergent extract or non-detergent extraction to separate the CSQ2 kinase from
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possible interfering phosphatases or ATPases that might account for this effect. We
found that linearity was partially restored with extractions carried out in detergent, and
more fully restored if detergents were removed (Fig. 20C,D). Whether restoration of
linearity was due to removal of CSQ2 phosphatase or cellular ATPases was not further
investigated. Based upon these determinations, CSQ2 kinase activities were generally
measured using 2 µg of mild detergent extract. Although the efficiency of CSQ2 kinase
extraction could not be determined in these experiments because of the non-linearity,
protein kinase CK2 recovery was only about 50% in detergent-free extracts based upon
immunoblot analyses (Fig. 20D, inset).
Pharmacological inhibition of CSQ2 phosphorylation in vitro
Because of our previous in vitro evidence implicating CK2 as CSQ2 kinase [36],
we tested the effects of new commercially available competitive inhibitors of CK2 [63]
on CSQ2 kinase activity in cell extracts. To allow us to compare effects of CK2-specific
inhibitors, we first normalized endogenous CSQ2 kinase activities in myocytes, COS
cells, and commercial CK2 by comparing their relative ability to phosphorylate 2 µg pure
CSQ2.

Based upon these determinations, one would calculate that about 0.07% of

cardiomyocyte protein and 1.7% of COS cell protein is CK2, if CK2 and CSQ2 kinase
are the same protein and purified CK2α' maintains its native activity. A value based
upon immunoblotting of pure CK2 and COS cell extracts was closer to 1% of total
protein, and consistent with a 25-fold lower level in cardiomyocytes (data not shown).
Equal CSQ2 kinase activities from all three sources were then used to test
inhibitors in vitro, using 2, 5, 10, 20, 50 or 100 µM concentrations of CK2-specific
inhibitors TBB [110], DMAT [111] and TBCA [60] (Fig. 21A-C). All three inhibitors were
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capable of inhibiting endogenous CSQ2 kinase activity in both cardiomyocyte and COS
cell extracts, and at concentrations similar to those required to inhibit commercial CK2
phosphorylation of CSQ2. The most potent of the three inhibitors was TBCA, which

Figure 21. Effects of CK2 inhibition on CSQ2 kinase activity. Measurements of
CSQ2 kinase activities were carried out as described in Experimental Procedures using
equivalent amounts of activity from cardiomyocytes (closed circles), COS cells (closed
squares), or pure CK2α' (open circles). Reactions included 0, 2, 5, 10, 20, 50 and 100
µM concentrations of the CK2 inhibitors TBB (A), DMAT (B) or TBCA (C) (structures
shown in respective insets). Activities are shown (y-axis) as percent of control
(untreated).

inhibited both endogenous CSQ2 kinase as well as commercial CK2 phosphorylation of
CSQ2 at an IC50 of about 10 µM. TBCA produced a near identical inhibition curve for all
three kinase source reactions (Fig. 21C).

TBB and DMAT were also capable of

inhibiting CSQ2 kinase and commercial CK2, but at higher micromolar concentrations
(IC50 approximately 50 and 60 µM, respectively). TBCA was chosen for subsequent
experiments in cultured cells because it is reportedly the most specific and potent
inhibitor of the three [60], and because we found TBCA to be the most soluble in culture
media (data not shown).
Pharmacological inhibition of CSQ2 phosphorylation in cultured cells
Our ability to inhibit cardiomyocyte and COS cell CSQ2 kinase in vitro, led us to
determine whether TBCA would inhibit phosphorylation of CSQ2 during its
overexpression in COS cells. For both cell types, CSQ2 was overexpressed using an
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adenovirus to achieve high levels of
biosynthesis

in

case

CSQ2

phosphorylation was tied to its rate of
translation.
using

32

We previously showed
Pi-labeling

cardiomyocytes

that

in

rat

endogenous

CSQ2 phosphorylation is very low
compared to similar amounts of
virally overexpressed CSQ2 [34]. In
experiments here, cardiomyocytes Figure 22.
and COS cells were treated with
Ad.CSQ for 24 h before an additional
treatment with either 100 µM TBCA
or vehicle (DMSO).

Levels of

endogenous phosphate on CSQ2
were determined from the difference
between CSQ2 phosphorylation with
and

without

phosphatase

pretreatment. We found that TBCA

Reduction in endogenous CSQ2
phosphorylation in cells treated with TBCA.
COS cells or cardiomyocytes (Heart) were treated
with Ad.CSQ for 24 h in culture, then DMSO (C) or
100 µM TBCA was added for 24 h. Cells were
extracted in mild-detergent, and levels of phosphate
on the overexpressed CSQ2 (Endog PP) were
determined for equal volumes of C or TBCA-treated
cell extracts using the front phosphorylation assay.
Endogenous phosphate on CSQ2 corresponds to
the difference in radioactivity between 32Pincorporation after and before acid phosphatase
(PPase) treatment. A sample autoradiogram is
shown for a measurement on partially purified CSQ2
protein from COS cells (upper panel). Results are
also shown for multiple analyses of endogenous
CSQ2-phosphate
content
following
its
overexpression
in
either
COS
cells
or
cardiomyocytes for C or TBCA-treated cells (lower
panel, means  S.E.M., n=3).

produced a potent inhibition of phosphate incorporation into CSQ2 in cultured
cardiomyocytes and COS cells of 82 and 66%, respectively, compared to vehicle
controls (Fig. 22). The reduced effect of TBCA on CSQ2 phosphorylation in COS cells
might just reflect the high levels of kinase in COS cells (Fig. 20B).
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siRNA knockdown of CK2 catalytic subunits
To corroborate the pharmacologic data that supported identification of CSQ2
kinase as CK2, RNAi experiments were performed. Three separate siRNA mixtures
that were tested were successful in silencing CK2α and CK2α' catalytic subunits at 100
nM in either HEK or COS cells, as determined by immunoblotting of cell homogenates
(Fig. 23A). CK2α and CK2α' siRNA with the greatest knockdown efficiencies were used

Figure 23. Knockdown of CK2α and CK2α' using siRNA. COS cells were
transfected for 48 h with siRNA against either CK2α or CK2α', then extracted in mild
detergent. (A) untreated cells (“C”) or siRNA-treated cell samples (50 µg) were analyzed
by immunoblotting using specific antibodies to detect CK2α (~40 kDa) or CK2α' (~35
kDa); compare to 45 kDa MW standard. (B) shows the average levels of CK2α and
CK2α' knockdown (si) as a percent of untreated (“C”) cells. (C) shows the effects of
CK2α plus CK2α' knockdown on CSQ2 kinase activity levels measured in detergent
extracts of treated (si) and untreated (“C") COS cells. Plots show means  S.E.M., n=3.

for subsequent experiments in cultured COS cells.
To determine the effect of CK2 knockdown on CSQ2 kinase activity, we
transfected COS cells with siRNA directed at both isoforms of the catalytic subunit.
Protein levels for both CK2 isoforms, determined by immunoblotting, were reduced by
approximately 95% over controls (Fig. 23B). Extracts prepared from these siRNA-cells
exhibited an approximate 2-fold reduction in CSQ2 kinase activity (Fig. 23C). This
decrease in CSQ2 kinase activity is notable given the high levels of CK2 present in
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COS cells (Fig. 20B) and the potential that siRNA does not silence all cellular pools of
CK2 equally, such as those with differing rates of protein turnover.

CSQ2 kinase

activities from cells following silencing of individual CK2 isoforms could not resolve
subunit-specific effects because of apparent compensatory changes in each CK2α

Figure 24. Reduction in endogenous CSQ2 phosphorylation in cells treated with
CK2 siRNA. COS cells were treated with Ad.CSQ for 24 h in culture, then transfected with
siRNA against CK2α plus CK2α' for an additional 48 h. (A) Cells were extracted in milddetergent, and levels of phosphate on partially purified CSQ2 (Endog PP) were
determined. Individual samples of CSQ2 were normalized by immunoblotting. A sample
autoradiogram is shown for purified CSQ2 samples for untreated control (“C”) and siRNAtreated COS cells (upper panel). Results are also shown (lower panel) from multiple
analyses of endogenous CSQ2-phosphate content for C and siRNA-treated cells
(meansS.E.M., n=4). (B) similar Ad.CSQ-treated COS cells (C or siRNA-treated) were
metabolically labeled with 35S[Met] for 2 h, and identical sample volumes were analyzed by
SDS-PAGE. The gel was stained with Stains-All to highlight CSQ2 as a dark-blue protein
band on a pink background (arrowhead), then destained and re-stained with Coomassie
blue, then dried and placed against film for autoradiography. MW standards (left) are in
kDa. The 66 kDa standard is albumin, which also contaminates the sample cultures from
the serum in the medium. (C) effects of CK2 siRNA on CSQ2 mRNA levels determined by
triplicate qPCR measurements (means  S.E.M., n=3).

isoform that occurred after 48 h of knockdown.
To determine whether CK2 knockdown would decrease the level of endogenous
CSQ2 phosphorylation in intact cells, COS cells overexpressing canine CSQ2 were
treated with CK2 siRNA. In accordance with the roughly 2-fold decrease in CSQ2
kinase activity caused by CK2 siRNA transfection (Fig. 23C), we measured a 2-fold
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decrease in the levels of phosphate in CSQ2 in COS cells (Fig. 24A). This loss of
endogenous phosphate occurred despite a 24 h period of overexpression prior to siRNA
treatment.

Moreover, even with CK2 protein diminishing over the course of the

treatment period, an ongoing phosphorylation of CSQ2 would have occurred due to the
exquisite affinity of CSQ2 for CK2 [36].
A complicating effect of CK2 siRNA in COS cells was an increase in protein on
SDS-gels, including significant changes in overexpressed CSQ2 (Fig. 24B).

The

change could be seen by protein stain, as well as following a 2 h [35S]methionine
labeling of cells. Analysis by qPCR of CSQ2 mRNA in treated and untreated cells
showed a roughly 2-fold increase (Fig. 24C). Whether transcriptional or translational
changes accounted for observed changes in cellular protein was not further
investigated. Measurements of CSQ2 phosphorylation were therefore carried out by
first purifying CSQ2 from cellular extracts, normalizing CSQ2 levels using antibody
binding (immunoblot) analyses, then using standard phosphate analysis assays.
Effects of CSQ2 phosphorylation site mutation on protein trafficking in
nonmuscle cells
To determine whether CSQ2 phosphorylation could affect its trafficking, we
examined purified wild-type CSQ2 (CSQ-WT) and phosphorylation-site mutants (Table
2) by electrospray mass spectrometry to determine the details of their polymorphic
structure [31]. CSQ-WT was composed primarily of molecules having glycans with
Table 2. CSQ2 phosphoform variants.

57

structures of GlcNAc2Man9 and GlcNAc2Man8 (Man9,8) with only minor amounts or no
Man7 (Fig. 25A).

In addition, these CSQ-WT molecules contained peaks of

phosphorylated protein with a spacing of 81 Da (Fig. 25A, shaded) as previously
described [23, 31].

Replacement of phosphorylatable serines with alanines (CSQ-

nonPP) led to loss of all CSQ2 phosphorylation along with the appearance of lowermass forms of the protein that correspond to increased levels of mannose trimming (Fig.
25B). We previously showed in COS cells that mannose trimming beyond Man9,8
occurs for CSQ2 molecules that are not efficiently retained in ER [23].

Figure 25. Effects of CSQ2 phosphorylation site sequence on glycan structure in
nonmuscle cells.
Cultured nonmuscle cells were treated with recombinant
adenoviruses encoding either the wild-type CSQ2 sequence (WT), the
Ser(378,382,386)Ala triple point mutant (nonPP), or the Ser(378,382,386)Glu mutant
(mimPP) for 48 h, then CSQ2 was purified and analyzed by mass spectrometry as
described in Experimental Procedures. Sample mass spectra are shown for each
purified sequence of CSQ2 (A-C). Numbers 5-9 refer to the number of mannoses in the
glycan that correspond to the mass values shown along the bottom axis. Minor levels of
peaks that differ in mass by 20-40 Da, are likely to correspond to cation-bound
molecules, and varied among spectra. Mannose content for the three CSQ2 structures
are shown as aligned, although there were minor differences in mass due to the
sequence mutations. Molecular weights (bottom) are those corresponding to the WT
sequence. (D) The percentages of total CSQ2 molecules that exhibited mannosidase
trimming to below 8 mannoses (non-ER glycan) are shown from multiple experiments
(means  S.E.M., n=3).
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To determine whether this effect on CSQ2 trafficking was purely due to the loss
of phosphorylatable serines, we carried out the same analysis following replacement of
serines with glutamates (CSQ-mimPP).

In contrast to CSQ-nonPP, CSQ-mimPP

molecules gave structures similar to that of CSQ-WT (Fig. 25C). Multiple spectra from
independent CSQ-WT, CSQ-nonPP and CSQ-mimPP samples were analyzed in order
to compare the percent of total CSQ2 leaving ER as represented by mannoses less
than 8 and 9 (Fig. 25D).

Thus, the CSQ2 kinase appears to be acting at a co-

translational site within the cell, and a resultant increase in CSQ2 phosphorylation may
alter its ability to exit that site of biosynthesis.
DISCUSSION
CSQ2 kinase as protein kinase CK2
In mammalian heart tissue, CSQ2 exists as a highly phosphorylated protein [31,
34, 36]. Endogenous phosphate is found only on a cluster of 2 or 3 serine residues
(depending upon the species) that are found in the cardiac C-terminal extension. This
CSQ2 phosphorylation reaction is essentially the same in all mammalian cells examined
to date, whether one examines native or overexpressed CSQ2 [23, 31]. In intact heart
tissue, CSQ2 appears to be phosphorylated early in its biosynthesis in rough ER based
upon the fact that newly synthesized molecules (Man 9,8,7) only exist in the fully
phosphorylated state, whereas the most highly trimmed glycans (Man 2,3,4) are mostly
devoid of phosphate [34].

A critical question that has remained unresolved in this

process, however, is whether the CSQ2 kinase is protein kinase CK2. We previously
showed that CSQ2 phosphorylation sites adhere closely to the consensus sequence for
protein kinase CK2, and CSQ2 is exquisitely sensitive to CK2 in vitro [12]. However, if
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CK2 is the CSQ2 kinase, it raises the important question of how CSQ2, a luminal ER
protein, can be phosphorylated by what is believed to be a cytosolic enzyme. CK2 has
no known mechanism for localizing to the ER/SR lumen where CSQ2 is thought to be
wholly contained throughout its lifetime [17]. Only when the CSQ2 C-terminus is in the
process of traversing the translocon pore complex could such an association
theoretically occur [32]. Such a process suggests that CSQ2 phosphorylation is a cotranslational event, and CK2 could be associated with the translocon, similar to the
association of the oligosaccharide transferase complex (OST) that brings about cotranslational N-linked glycosylation. CK2 has previously been shown to play a role in
assembly of the translocon pore complex and signal sequence through phosphorylation
of sec63 [112]. Calnexin, another resident ER protein, is a transmembrane protein that
undergoes interaction with the ribosome in response to phosphorylation of its
cytosolically exposed CK2 site [56]. We have previously reported that a number of
resident ER/SR proteins are substrates for CK2 in vitro [17], perhaps suggesting that
the reaction mechanism described in this paper may play a wider role in ER/SR biology.
To show that protein kinase CK2 is the physiological enzyme that modifies CSQ2
in vivo, this series of studies altered the reaction in a mammalian nonmuscle cell model
system. Based upon our data from several experimental approaches, we conclude that
CK2 is likely to be the native CSQ2 kinase that is present in all mammalian cells. This
necessitates a co-translational or co-translocational phosphorylation event occurring for
CSQ2. The differences we found in the glycan structures of CSQ2 phosphorylation site
mutants support this conclusion, indicating that a proximal phosphorylation event affects
subsequent CSQ2 trafficking, reflected in its mannose trimming, within the secretory
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pathway.
CSQ2 kinase activity and its inhibition
Whether CK2 activity was competitively inhibited using TBCA, a highly specific
inhibitor of CK2 [60], or biospecifically down-regulated using RNAi technology, CSQ2
kinase activity was affected in parallel. These data show that the CSQ2 kinase that
exists in preparations derived from all mammalian cells [23] is likely the result of protein
kinase CK2. Reduced levels of CSQ2 kinase that remain in cell extracts following CK2
inhibition or down-regulation, we believe, are unlikely to emanate from a second
unknown CSQ2 kinase, although further studies may be warranted.
The advent of highly specific inhibitors of CK2 has also been driven by the fact
that these compounds exhibit anti-growth and anti-cancer activities [58-59], reflecting an
important role of CK2 in cell growth. The fact that CSQ2 is the major substrate for CK2
in heart homogenates is consistent with a possible role of CSQ2 phosphorylation in
cardiac hypertrophy. We have previously shown that CSQ2 phosphorylation is doubled
in canine tachycardia-induced heart failure [35].
In contrast to the relatively immediate inhibition of all available CK2 catalytic
subunits using TBCA, siRNA inhibition was expected to be more gradual requiring
turnover of the existing kinase pool, as suggested by Zhu et al. [59]. Furthermore, we
cannot be certain that turnover of all CK2 pools within the cell are the same, whereas
ATP binding sites are likely to be identical. Because both subunits are capable of
efficiently phosphorylating CSQ2 in vitro (data not shown), simultaneous CK2α/α′
knockdown was needed to verify the identity of CK2 as CSQ2 kinase. Analysis by
immunoblot usually showed a putative compensatory increase in subunit partner in
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single subunit down-regulation experiments that was not further investigated. In spite of
these differences in mechanisms, both CK2 inhibition techniques produced qualitative
decreases in CSQ2 kinase activity, and each was able to lower phosphate incorporation
in overexpressed CSQ2. Minor quantitative differences in the degrees of CSQ2 kinase
inhibition were likely to have reflected their very different mechanisms of CK2 inhibition.
Experimental

determinations

of

CSQ2

kinase

and

phosphorylation

Measurements of in vitro CSQ2 phosphorylation were found to be surprisingly
nonlinear; and in fact produced lower levels of CSQ2 phosphorylation using higher
levels of protein in the phosphorylation assay. In principle, the problems we uncovered
should plague any and all determinations of kinase activity in crude preparations, such
as those used in this study. Our data suggest that endogenous ATPases represent
potentially confounding activities, such that it is necessary to use minimal cellular
protein extract along with mild extraction techniques to accurately determine in vitro
phosphorylation rates. Understanding these limitations, we were able to demonstrate
the potential utility of these CK2 inhibitors for use as cellular probes.
Studies aimed at determining effects of CK2 reduction on phosphate levels in
CSQ2 were carried out in CSQ2-adenovirus treated cells. As previously observed from
32

P-labeling reactions in cultured rat cardiomyocytes [34], the higher rate of CSQ2

biosynthesis

obtained

through

Ad.CSQ2

treatment

was

needed

to

observe

phosphorylation, presumably because of its elevated rate of biosynthesis and cotranslational phosphorylation.

CK2 silencing itself, however, produced increases in

cellular and CSQ2 protein synthesis that affected steady state protein levels after 48 h
in culture, as well as [35S]Met incorporation over a 2 h period (Fig. 24B).

CSQ2
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purification, however, permitted measurements of CSQ2 phosphorylation state by using
our standard assay with equal amounts of CSQ2. Thus, reductions of CK2 activity
through either of two separate approaches in cultured cells reduced levels of cellular
CSQ2 kinase activity, and reduced endogenous CSQ2 phosphate content.
Protein kinase CK2 regulation of CSQ2 trafficking
Based upon identification of CSQ2 kinase in intact cells as the cytosolic protein
kinase CK2, our previous hypothesis that CSQ2 phosphorylation is a co-translational

Figure 26. Hypothetical mechanism of cardiac CSQ phosphorylation by CK2 in rough
ER during translocation across the ER membrane. A mechanism whereby an ER
protein such as CSQ2 becomes exposed to cytoplasmic CK2 would require that the ERbound ribosome permits access to the nascent CSQ2 polypeptide after completion of
translation but during its translocation through the translocon. Other known translocon
accessory proteins, such as TRAP and TRAM [99] are present in cardiomyocyte rough ER
and could function in such translocational regulation [64].

event [34] can be expanded. In our new model (Fig. 26), we hypothesize that CSQ2
phosphorylation occurs before the C-terminal tail has entered the lumen of the protein
pore complex (sec61) or ER lumen [113].

One possible mechanism might be a

translocation pause wherein the ribosome separates from the translocon permitting a
transient co-localization of CK2 and CSQ2 [64, 113]. If such a process, so proximal in
the secretory pathway, were to affect the subsequent trafficking of CSQ2 through the
secretory pathway, mannose trimming alterations would not be unexpected.
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Intracellular localization of CSQ2 can consistently be predicted from its N-linked
glycan structure in a number of mammalian cell types including cardiomyocytes. In this
study, comparisons of glycan structures for CSQ-WT, CSQ-nonPP, and CSQ-mimPP
showed that only the CSQ-nonPP form exhibits excessive mannose trimming, indicative
of increased trafficking away from rough ER.

Glutamate, a commonly used

phosphomimetic substitution, showed a marked reversal of this effect on glycan
structure. These results support the idea that CSQ2 phosphorylation is associated with
its biosynthesis and affects retention of CSQ2 in ER.
In heart failure, the detailed structure of CSQ2 is dramatically shifted. A peak of
newly synthesized CSQ2 (with Man9,8 glycans) accumulates instead of continuing
through its normal trafficking cycle [35], indicating that this newly synthesized protein is
being retained within rough ER structures.

Rough ER, as we have recently

demonstrated, is localized to juxtanuclear cisternae in cardiomyocytes [99]. Together
with findings reported here, we hypothesize that changes in CK2 activity and/or
localization in heart failure increase CSQ2 phosphorylation with consequent ER
retention, to favor a perinuclear Ca2+ microdomain shift facilitating increased
transcription or translation in hypertrophy.
CONCLUSIONS
In conclusion, findings generated from multiple experimental approaches in this
study support an emerging picture of CSQ2 phosphorylation as a co-translational
process, which we now hypothesize is co-translocational as well. Verification that CK2
is the in vivo CSQ2 kinase implicates the involvement of the rough ER translocon in this
biological reaction.

The dependence of CSQ2 glycan structure on its state of
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phosphorylation has consistently revealed important features of this reaction, both here
using CSQ2 phosphorylation site mutants as well as for CSQ2 in failing hearts. These
studies should guide future investigations by establishing a basic biochemical paradigm
for CSQ2 phosphorylation in the mammalian cell.
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CHAPTER 4
SUMMARY
Cardiac CSQ is a multifaceted protein, capable of binding significant quantities of
Ca2+ and altering RyR2 activity at junctional SR. The site of CSQ2 synthesis, however,
is not junctional SR. This fact has been largely overlooked in the field of cardiac cell
biology, coinciding with a tendency to picture protein distribution in the cardiomyocyte
as a static system. The reality is that CSQ2 is constantly being made and trafficked
from its site of biosynthesis in perinuclear rough ER to junctional SR in a
polymer/monomer, phosphorylation-dependent manner.
With the majority of cardiac biochemists focusing on junctional SR Ca2+ release,
little thought has been given to the basic questions that one assumes would have been
answered prior to the study of complex cell biology. Accordingly, the location of rough
ER in cardiomyocytes has never been elucidated. There is often a comparison between
skeletal muscle myocytes, for which cell biology is slightly more established, and
cardiac myocytes.

This extrapolation may not be applicable in terms of protein

synthesis however as traditional cell biology dictates that rough ER surrounds the
nucleus and would therefore increase if more nuclei were present. This is the case as
skeletal muscle cells are polynucleated while cardiac muscle cells are binucleated in a
symmetrical manner.
Through the use of multiple antibodies specific to classic rough ER markers, and
with the CSQ-DsRed fusion protein, we were able to establish a juxtanuclear
localization of rough ER in cardiomyocytes. Using fluorescence confocal microscopy,
the translocon complex proteins TRAP-α and TRAM, along with the ribosomal protein
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S6, were all visualized and found to encapsulate both myonuclei. Additionally, time
course studies of the CSQ-DsRed tetramer, in conjunction with anti-DsRed
immunostaining, highlighted a perinuclear rough ER site of biosynthesis for CSQ2 and
presumably all other proteins in the secretory system.
Following CSQ-DsRed translation, the fusion protein built up in the ER
surrounding the nuclei due to DsRed tetramerization, and then trafficked anterogradely
to junctional SR.

Filling of more peripheral junctional SR puncta occurred with

increasing incubation time. With the exception of CSQ-DsRed concentration around the
nuclei, DsRed fusion protein tetramerization-dependent trafficking is predicted to be
very similar to CSQ2 polymerization-dependent trafficking likely caused by the Ca2+
properties of secretory pathway compartments.
Cardiac-specific C-terminal phosphorylation of CSQ2 serines was also shown to
effect CSQ2 trafficking according to mass spectrometric analysis of the protein’s Nlinked glycan. A Ser 378,382,386 Ala mutation (CSQ-nonPP) of these sites inhibited
CSQ2 phosphorylation and led to an increased trafficking out of the ER as indicated by
the increased mannose trimming of CSQ2 glycan. This effect was reversed with the
phosphomimetic mutant Ser 378,382,386 Glu (CSQ-mimPP) which had glycoforms with
mannose trimming nearly identical to that of CSQ-WT.
Pharmacological and molecular inhibition were used to establish the identity of
CSQ2 kinase as protein kinase CK2. In vitro, inhibition of CSQ2 phosphorylation using
cardiomyocyte and nonmuscle cell CSQ2 kinase sources was successfully carried out
with three specific inhibitors of CK2: TBB, DMAT and TBCA. TBCA produced identical
inhibition curves for both cellular kinase sources and commercial CK2α′ kinase, with
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increasing concentrations of drug. SiRNA knockdown of both CK2α and CK2α′ catalytic
subunits in nonmuscle cells reduced CSQ2 kinase activity by nearly 2-fold according to
similar in vitro CSQ2 phosphorylation assays.
Additionally, both ATP-binding site competitive inhibition and CK2 RNAi protein
inhibition

were

used

successfully

in

situ

to

suppress

endogenous

CSQ2

phosphorylation. TBCA used at 100 µM with CSQ-WT overexpressing cardiomyocytes
and COS nonmuscle cells in culture led to an 82 and 66% decrease in CSQ2 phosphate
incorporation, respectively, compared to control. Similarly, simultaneous knockdown of
both CK2α and CK2α′ catalytic subunits in COS cells overexpressing adenoviral CSQWT, caused a near 2-fold decrease in CSQ2 phosphate incorporation, further
supporting the identity of CSQ2 kinase as protein kinase CK2.
These studies present a global model for CSQ2 trafficking regulation in
cardiomyocytes.

As CSQ2 is translated at perinuclear rough ER, its C-terminus is

exposed to the cytosolic protein kinase CK2 allowing for CSQ2 phosphorylation prior to
translocation into the ER lumen.

A combination of dephosphorylation and

monomerization then promote anterograde trafficking through the secretory system.
CSQ2 subsequently becomes retained in junctional SR compartments due to increasing
Ca2+ concentrations, which leads to polymer formation. Following a decrease in Ca2+
levels, CSQ2 monomerizes to once again traffic anterogradely through the secretory
system.
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APPENDIX
LIST OF ABBREVIATIONS
Ad.CSQ

wild-type cardiac calsequestrin adenovirus

Ad.CSQ-DsRed

adenoviral cardiac calsequestrin-DsRed

Ad.CSQ-HA

adenoviral cardiac calsequestrin with hemagglutinin epitope tag

Ad.mimPP

constitutively-phosphorylated cardiac calsequestrin adenovirus

Ad.nonPP

nonphosphorylatable cardiac calsequestrin adenovirus

CICR

calcium-induced calcium release

COS

COS-7 African green monkey kidney cells

CPVT

catecholaminergic polymorphic ventricular tachycardia

CSNK2A1

protein kinase CK2α catalytic subunit

CSNK2A2

protein kinase CK2α′ catalytic subunit

CSQ

calsequestrin

CSQ-DsRed

cardiac calsequestrin pDsRed2-N1 fusion protein

CSQ-mimPP

constitutively-phosphorylated cardiac calsequestrin

CSQ-nonPP

nonphosphorylatable cardiac calsequestrin

CSQ-WT

wild-type cardiac calsequestrin

CSQ1

skeletal calsequestrin

CSQ2

cardiac calsequestrin

CSQ-HA

cardiac calsequestrin with hemagglutinin epitope tag

DAPI

4′-6-diamidino-2-phenylindole

DMAT

2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole

DMEM

Dulbecco’s Modified Eagle’s Medium
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DRB

5,6-dichloro-1-(β-ɒ-ribofuranosyl)-benzimidazole

DsiRNA

Dicer-Substrate siRNA

ECL

electrochemiluminescence

ER

endoplasmic reticulum

ERGIC

ER-Golgi intermediate compartment

ESMS

electrospray mass spectrometry

GlcNAc

N-acetyl-D-glucosamine

HEK

human embryonic kidney 293 cells

HF

heart failure

HRP

horseradish peroxidase

IP3R

inositol trisphosphate receptor

Jct

junctin

Man

mannose

MOI

multiplicity of infection

NCX

Na+/Ca2+ exchanger

OST

oligosacharyl transferase complex

RNC

ribosome nascent chain complex

RyR

ryanodine receptor

RyR2

cardiac ryanodine receptor

SERCA2a

cardiac sarco/endoplasmic reticulum Ca2+-ATPase

SP/SPC

signal peptidase complex

SR

sarcoplasmic reticulum

SRP

signal recognition particle
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SRP-R

signal recognition particle receptor

T-tubules

transverse tubules

TBCA

tetrabromocinnamic acid

TBB

4,5,6,7-tetrabromobenzotriazole

TRAM

translocating chain-associated membrane protein

TRAP

translocon-associated protein complex

Trd/Trd1

triadin-1
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Cardiac CSQ (CSQ2) is a multifaceted protein, capable of binding significant
quantities of Ca2+ and altering ryanodine receptor activity at the junctional sarcoplasmic
reticulum (SR). Little is known about the trafficking of CSQ2 from its unknown site of
biosynthesis, which appears to be of importance as its structure changes in a traffickingdependent manner in various types of heart failure.

Through the use of multiple

antibodies specific to classic rough ER markers, and with the creation of CSQ-DsRed
tetramer fusion protein, we were able to establish a juxtanuclear localization of rough
ER in cardiomyocytes.

Using fluorescence confocal microscopy, the translocon

complex proteins TRAP-α and TRAM, along with the ribosomal protein S6, were all
visualized and found to encapsulate both myonuclei. Additionally, time course studies
of CSQ-DsRed, in conjunction with anti-DsRed immunostaining, highlighted a
perinuclear rough ER site of biosynthesis for CSQ2. The fusion protein exhibited a
tetramerization-dependent

trafficking

predicted

to

be

very

similar

to

CSQ2

polymerization-dependent trafficking with high and low secretory compartment Ca2+
concentrations leading to polymerization and monomerization, respectively.
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Cardiac-specific C-terminal phosphorylation of CSQ2 serines was shown to
effect CSQ2 trafficking according to mass spectrometric analysis of the protein’s Nlinked glycan. A Ser 378,382,386 Ala mutation (CSQ-nonPP) of these sites inhibited
CSQ2 phosphorylation and led to an increased trafficking out of the ER as indicated by
the increased mannose trimming of CSQ2 glycan. This effect was reversed with the
phosphomimetic mutant Ser 378,382,386 Glu (CSQ-mimPP) which had glycoforms with
mannose trimming nearly identical to that of CSQ-WT.
Pharmacological and molecular inhibition were used to establish the identity of
CSQ2 kinase as protein kinase CK2. In vitro, inhibition of CSQ2 phosphorylation using
cardiomyocyte and nonmuscle cell CSQ2 kinase sources was successfully carried out
with three specific inhibitors of CK2: TBB, DMAT and TBCA. TBCA produced identical
inhibition curves for both cellular kinase sources and commercial CK2α′ kinase, with
increasing concentrations of drug. SiRNA knockdown of both CK2α and CK2α′ catalytic
subunits in nonmuscle cells reduced CSQ2 kinase activity by nearly 2-fold according to
similar in vitro CSQ2 phosphorylation assays.
Additionally, both ATP-binding site competitive inhibition and CK2 RNAi protein
inhibition

were

used

successfully

in

situ

to

suppress

endogenous

CSQ2

phosphorylation. TBCA used at 100 µM with CSQ-WT overexpressing cardiomyocytes
and COS nonmuscle cells in culture led to an 82 and 66% decrease in CSQ2 phosphate
incorporation, respectively, compared to control. Similarly, simultaneous knockdown of
both CK2α and CK2α′ catalytic subunits in COS cells overexpressing adenoviral CSQWT, caused a near 2-fold decrease in CSQ2 phosphate incorporation, further
supporting the identity of CSQ2 kinase as protein kinase CK2.
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These studies present a global model for CSQ2 trafficking regulation in
cardiomyocytes.

As CSQ2 is translated at perinuclear rough ER, its C-terminus is

exposed to the cytosolic protein kinase CK2 allowing for CSQ2 phosphorylation prior to
translocation into the ER lumen.

A combination of dephosphorylation and

monomerization then promotes anterograde trafficking through the secretory system.
CSQ2 subsequently becomes retained in junctional SR compartments due to increasing
Ca2+ concentrations, which led to polymer formation. Following a decrease in Ca2+
levels, CSQ2 monomerizes to once again traffic anterogradely through the secretory
system.
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